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Abstract 
Hypertension and dyslipidemia may frequently coexist, and together have an increase in 
coronary heart disease related events. Combination therapy of rosuvastatin calcium and 
amlodipine besylate, effective for the control of hypertension by substantially reducing blood 
pressure and cholesterol levels, can improve its control rates to well above 80% rather than a 
single pill for hypertension which will control no more than 50% of a hypertensive population. 
The objective of the present study was to develop and validate a simple, selective and 
reproducible RP-HPLC method according to the ICH guidelines for the simultaneous estimation 
of rosuvastatin calcium and amlodipine besylate in their combined dosage forms and for drug 
dissolution studies. The method involves gradient elution of drugs in a stationary phase of  Luna 
5µ C18 column (250 mm x 4.60 mm) using a mobile phase mixture of acetonitrile and phosphate 
buffer of pH 2.5 in the ratio 45:55 % v/v, with a flow rate of 1.5 ml/min in ambient temperature 
for separation and quantification of the drugs. The injection volume was 10µl and ultraviolet 
detector was set at 240 nm. Total runtime was less than 9 minutes. Under the above mentioned 
conditions, the system was found to elute rosuvastatin calcium at approximately 6.08 mins 
(Assay), 6.17 mins (dissolution) and amlodipine besylate at approximately 2.5 min (dissolution), 
2.7 min (assay). Linear regression analysis data for the calibration plots showed good linear 
relationship with r2= 0.993 with respect to peak area in the concentration range 8 -1.2 µg/ml for 
rosuvastatin and r2= 0.996 with respect to peak area in the concentration range 4-6 µg/ml 
concentration of amlodipine. The percent of recovery was found to be in the range of 98-102% 
for both the drugs. The developed and validated assay method was found to be accurate, precise, 
robust and specific which allows its adoption for the routine quality control in-vitro dissolution 
studies of both the pure drug and the combination formulation. 
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Chapter 1 
Introduction 
Analysis is basically the study of separating, identifying and determining the relative amount of 
components of natural and artificial materials for characterizing it both quantitatively and 
qualitatively.  Qualitative analysis gives an indication of the identity of the chemical species in 
the sample whereas quantitative analysis determines the amount of certain components in the 
sample. It is notable that most of the analytical tests are based on measuring specified 
components in the presence of a sample matrix and/or related substances and consequently 
isolation or separation of the target analytes preceding quantitative and qualitative analysis 
becomes compulsory. By using optimized separation techniques, it is possible to monitor the API 
(for assay), organic synthetic process impurities, and degradation products during a single 
determination.  Chemically separations can be achieved by using chromatographic method and to 
a much lesser extent by electrophoresis. In chromatographic method, separation is achieved by 
variable distribution of different components between two dissimilar phases—a stationary phase 
and a mobile phase; and in electrophoresis, separations are done based on the difference in the 
motilities of the analytes within a conductive liquid medium subjected to an electric field. 
Solutes are separated based on differences in their hydrodynamic size-to-charge ratios 
(Scypinski, 2001). Knowing the ratio of mobility to hydrodynamic radius allows the charge, or 
valence, of the molecule to be determined (Actipix, 2010).  
Analytical performance can be done either by instrumental method or classical method to 
identify and quantify compounds. Classical method ascertains the color, odor, or melting point of 
smaller entity for their qualitative analysis and measure weight or volume for their quantitative 
analysis. The separation technique under classical method includes precipitation, extraction, 
and distillation . In respect to the classical method, instrumental method is a newer concept to 
determine chemical species of organic, inorganic and biochemical analytes and has replaced 
classical method which enables sensitive, fast, reliable determination of small amount of 
complex sample.  This method uses a mechanical apparatus to determine the physical properties 
of organic inorganic and biochemical analytes such as light absorption or emission, mass to 
charge ratio, fluorescence, electrode potential or conductivity for quantitative and qualitative 
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analysis. Therefore, the application of instrumental technique for qualitative and quantitative 
analysis is diverse and on account of its sophistication in analysis, it has shown its immense 
contribution in textile analysis, chemical analysis, food purity analysis, microbial analysis, 
nutritive analysis, biotechnological analysis and genetical analysis. Instrumental analysis is 
mainly accomplished by spectrophotometric, electrochemical, chromatographic and thermal 
analytical methods (Figure 1). 
While developing any formulation, compatibility study of a drug with excipients must be done to 
support product development and improvement. A formulation is a composition containing 
active pharmaceutical ingredient (API) and other inactive ingredients known as excipients. To 
serve specific purposes of ensuring product performance, formulation must be chemically and 
physically stable throughout the manufacturing process and product shelf life along with their 
optimum bioavailability. Excipient compatibility studies are conducted to predict their possible 
compatibility with the target drug and justification of their usage. Therefore, while designing any 
new formulation studying the compatibility of single API with excipients or combined drug 
product with each other and excipients by various analytical techniques is imperative.  An 
undesirable drug interaction of one or more components results in changes physical, chemical, 
microbiological or therapeutic properties of the dosage form (Qiu et al., 2009). Besides, if the 
combined dosage form is formulated, incompatibility may arise in between the two API.  So the 
possible incompatibilities among the formulated ingredients need to be studied to select the 
dosage form’s compatible ingredients and to establish the stability profile. The analytical testing 
for drug-excipient compatibility study can be done as follows: 
1. Thermal method of analysis 
a) DSC- differential scanning calorimetry 
b) DTA- Differential thermal analysis. 
2. FT-IR Spectroscopy 
3. DFS- Diffuse reflectance spectroscopy 
4. Chromatography 
a) TLC- Thin layer Chromatography 
b) SIC-Self interactive chromatography 
5. Miscellaneous 
a) Fluoroscence spectroscopy 
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Figure-1: Classification of instrumental technique 
INSTRUMENTAL METHOD  
SPECTROMETRIC 
TECHNIQUE 
CHROMATOGRAPHIC 
TECHNIQUE 
ELECTROCHEMICAL 
TECHNIQUE 
1. UV & visible  spectroscopy 
2. Fluorescence & 
phosphorescence 
spectrophotometry 
3. Infrared spectroscopy 
4. Atomic absorption 
spectrophotometry 
5. Nuclear magnetic resonance 
spectrophotometry 
6. Electron spin resonance 
spectrophotometry 
7. Diffuse Reflectance 
Spectrometry 
8. X-ray spectrophotometry 
1. Ultra Pressure Liquid  
chromatography (UPLC) 
2. High Performance Liquid 
Chromatography (HPLC) 
3. High Performance Thin 
Layer Chromatography 
(HP-TLC) 
4. Gas chromatography (GC) 
5. Liquid 
Chromatography(LC)
1. Ampereometry 
2. Voltametry 
3. Potentiometry 
4. Colorimetry 
5. Electrogravimetry 
6. Conductance 
technique 
7. Stripping technique 
EMR is used  EMR is not used 
Mass 
spectroscopy 
Hyphenated method: 
1. GC-MS (Gas chromatography-Mass 
spectroscopy 
2. ICP-MS (Inductivity coupled plasma 
spectroscopy) 
3. GC-IR (Gas Chromatography-
Infrared spectroscopy) 
4. HPLC-tandem mass spectroscopy 
5. LC-MS/MS 
Thermal Analysis: 
1. Differential Thermal 
analysis (DTA) 
2. Differential scanning 
calorimetry (DSC) 
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b) Vapour pressure osmometry 
The pharmaceutical products are generally formulated in specific dosage forms with the 
objective of delivering the drug effectively to patients. While developing any formulation 
different experimentation is done for the evaluation of strength, quality, purity, potency and 
optimum bioavailability of the API in that specific dosage form to ascertain its efficacy. 
Therefore, the selection of the appropriate method along with process optimization and 
validation of that method by changing one or more variables to assure the suitable and accurate 
evaluation of any product against its defined specification and quality attributes prior to the 
manufacture of the dosage form is necessary. Once a method is developed and validated for any 
particular product then that can be used for routine analysis. Method development and validation 
is done usually for the quality evaluation of new emerging drugs. However, sometimes changes 
in the method need to be done when the method remains no longer suitable for its intended use. 
The change may be covered by the existing validation, in which case no further validation is 
required or the change may result in revalidation, and in some cases, redevelopment of the 
method followed by validation of the new method (McPolin, 2009).  
Combined dosage forms of two or more drugs have been proved useful in multiple therapies as 
they have better patient compliance than a single drug. It is well recognized that a single drug, 
even when used in maximal recommended dosage will control no more than 50% of a 
hypertensive population (Shaikh et al., 2010). On the other hand, the skillful use of two or more 
agents in combination can improve hypertension control rates to well above 80% (Shaikh et al., 
2010). Physicians often have a misguided belief that blood pressure can be controlled with a 
single drug and demonstrate to change or to add medications in those patients whose blood 
pressure are not at recommended goals (Shaikh et al., 2010). Therefore, the combination drug 
therapy is recommended for the treatment of hypertension to allow medications of different 
mechanism of action to complement each other and together effectively lower blood pressure at 
lower than maximum dosage of each (Atram et al., 2009). Hence, the analytical chemistry has 
thrown challenges in developing the methods for their analysis with the help of a number of 
analytical techniques, which are available for the estimation of the drugs and their combination.  
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As the title of the project suggests, the study has used instrumental techniques for pharmaceutical 
analysis to evaluate the efficacy of the proposed formulated combined dosage form using a 
calcium channel blocker (appendix 1) & a statin (appendix 2). 
For the drug-excipient compatibility study of rosuvastatin and amlodipine, FTIR testing has been 
done because of their sophisticated techniques in determining precisely the compatibility 
between the rosuvastatin calcium (appendix 3) and amlodipine besylate (appendix 4) along with 
their compatibility with the excipients. FT-IR, Fourier Transform Infrared Radiation, is the study 
of the interaction of electromagnetic radiation from the IR region of the EM spectrum (4000-
400) cm-1 with a molecule where absorption of certain frequencies of the radiation by the atoms 
of the substance leads to molecular vibration (appendix 5). The frequencies of absorbed radiation 
are unique for each atom or group of atom, which provide the characteristics of bonds associated 
with a substance. Usually if incompatibility arises during FTIR study for any particular 
excipient, DSC (Differential Scanning Calorimetry) study, which is a thermo analytical 
technique, is done for further confirmation of incompatibility. Other compatibility studies for 
further confirmation can be conducted but was not done in the present study due to time 
constraints. Method development and validation of the analytical assay method of the 
combination formulation of rosuvastatin calcium and amlodipine besylate was then done to 
verify the sensitivity of detecting rosuvastatin and amlodipine in their combination tablet dosage 
form according to USP & ICH guidelines. In vitro dissolution of rosuvastatin and amlodipine 
containing tablets were also performed to validate the suitability of the proposed method. The 
process flow chart of the present study is shown in Figure 2. 
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Figure-2: Flowchart of the study design of the project 
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1.1 Rationale of the study  
Cardiovascular diseases such as coronary heart disease, cerebrovascular disease, 
atherothrombosis, ischemic heart disease, peripheral arterial disease are found to be prevalent 
among different age groups of people especially among the young generation. The current trend 
of fast food intake, imbalance diet control, modernization and urbanization, busy work schedule 
are dominating factors behind the rapid increase in cardiovascular disease. Although there have 
been many advances in the management of cardiovascular diseases (CVD) during the last several 
years, these are still the main cause for morbidity and mortality (Gowda et al., 2012). 
Hypertension and dyslipidemia are important, modifiable cardiovascular (CV) risk factors that 
frequently coexist, and together have an increase in coronary heart disease related events that 
may be greater than expected from the simple addition of the risk associated with each condition 
(Blank et al., 2005). Treatment with the combination of two or more drugs may be much 
effective in multiple therapies in reducing the rate of cardiovascular events than treatment with 
single formulation imparting monotherapies. It is well recognized that a single drug, even when 
used in maximal recommended dosage will control no more than 50% of a hypertensive 
population (Shaikh et al., 2010). On the other hand, the skillful use of two or more agents in 
combination can improve hypertension control rates to well above 80% (Shaikh et al., 2010). 
Therefore, the rational for combination therapy is to encourage the use of lower doses of drug to 
reduce patient’s blood pressure with the goal to minimize dose dependent side effects and 
adverse reactions (Atram et al., 2009). Antihypertensive and lipid-lowering medications by 
substantially reducing blood pressure and cholesterol levels can lead to a large reduction of 
cardiovascular attack events. 
The fixed-dose combination containing the antihypertensive agent amlodipine and the 
cholesterol lowering agent atorvastatin is the first combination of its kind designed to treat two 
risk factors for cardiovascular disease (Devabhaktuni et al., 2009). Due to the hydrophobicity of 
atorvastatin, it has rapid access to non hepatic tissues which results in some undesirable side 
effects. Although the unwanted side effects associated with combined dosage of atorvastatin and 
amlodipine however has been found to be reduced when rosuvastatin is used in place of 
atorvastatin. Rosuvastatin, another member of the drug class statin, is hydrophilic and this makes 
them hepatoselective. This drug may thus be considered as a substitute of atorvastatin to 
Introduction 
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formulate a new combination of drug for dose-related reduction in systolic blood pressure, 
diastolic blood pressure and LDL-C in patients with co-morbid hypertension and dyslipidemia. 
Amlodipine is the choice of drug as an antihypertensive for the study owing to their long 
duration of action and comparatively higher oral bioavailability compared to the other calcium 
channel blockers due to their positive charge.  Amlodipine is more vasoselective with lower 
negative inotropic effects as well as reflex tachycardia is less prominent since fluctuations in 
plasma levels are less pronounced with these agents (Drug information, 2003).  Moreover, am-
lodipine has antioxidant effects, independent of calcium channel modulation, and a vasodilatory 
effect via the inhibition of nitric oxide release, which inhibits platelet aggregation. These 
pleiotropic effects of amlodipine suggest that it is more cardio protective than other non-CCB-
based treatments (Park, 2014). 
In order to elucidate the dissolution profiles of rosuvastatin and amlodipine, a simple, accurate, 
reproducible reverse phase HPLC assay method has been developed and validated and the 
method has been applied for the simultaneous determination of these drugs in dissolution matrix 
to validate the suitability of the proposed method since no systemic studies on the design and 
development of such a combination formulation or its in vitro dissolution study are currently 
available in literature. Thus, a simple, accurate, efficient and reproducible reverse phase HPLC 
method has been developed and validated for the simultaneous determination of rosuvastatin 
calcium & amlodipine besylate at 240 nm in combined tablet dosage form and has been applied 
successfully for in vitro dissolution studies. 
1.2 Literature review 
The study commenced with an extensive review of literature. The papers related to the present 
study were selected and information was reviewed. Several HPLC methods have been described 
for the determination of amlodipine when used alone (Avadhanulu, 1996; Basavaiah, 2005; 
Fang, 2007; Li, 2006 ; Patki, 1994; Shang, 1996, Ustun, 2006) and in combination with 
atorvastatin (Acharjya, 2010; Chaudhari, 2010; Freddy, 2005; Mohammadi,  2007; Rajkondawar, 
2006; Shah, 2006; Sivakumar, 2007, Haritha, 2014), with rosuvastatin (Banerjee, 2013; Tajane, 
et al., 2012) and with olmesartan medoxomil (Patil, 2001). Similarly, a 
survey of the analytical literature for HPLC, UV spectrophotometric determination of 
rosuvastatin when used alone (Chakraborty, 2011; Babu, 2014) and in combination with 
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ezetimibe (Anuradha et al., 2010), amlodipine (Banerjee, 2013; Tajane et al., 2012) in 
pharmaceutical preparations has also been described. The HPLC method described for 
simultaneous determination of rosuvastatin and amlodipine in pharmaceutical preparations 
(Banerjee, 2013; Tajane et al., 2012) however, are not developed for in-vitro dissolution profile 
of rosuvastatin calcium and amlodipine besylate from their combination drug product and thus 
has not been reported in the literature. 
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Chapter 2  
Methodology 
The research methodology of this project has been developed based on a proposed combination 
formulation of statins with calcium channel blocker. In the study, rosuvastatin, a member of 
statin has been combined with calcium channel blocker amlodipine, in the amount of 10 mg and 
5 mg respectively. Excipients have been chosen on the basis of the existing formulation of 
atorvastatin and amlodipine and their compatibility with the active ingredients has been verified. 
The proposed formula of the combination drug is given below (Table 1): 
Table 1: Proposed Formula of the combination drug 
Excipient Justification (of use) 
Pregelatiized starch Filler 
Microcrystalline Cellulose Binder 
Sodium starch glycolate Disintegrate 
Colloidal Sillicon Dioxide Glidant 
Butylated Hydroxyanisole Antioxidant 
Magnesium stearate Lubricant 
2.1 Excipient compatibility study 
While developing any formulation, excipient compatibility studies are done to select the viable 
excipients that are physically and chemically compatible with the API. In the present research, 
FT-IR study was conducted to verify the compatibility of the two APIs, rosuvastatin calcium and 
 
Active Pharmaceutical Ingredients 
 
Amount 
 
Rosuvastatin (as Rosuvastatin calcium) 
 
10 mg 
 
Amlodipine (as Amlodipine besylate) 
 
5mg 
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amlodipine besylate with the chosen excipients. FT-IR, Fourier Transform Infrared spectroscopy 
is the study of the interaction of electromagnetic radiation from the IR region of the EM 
spectrum (4000-400) cm-1 with a molecule through which IR radiation is passed.  The nature of 
interaction depends upon the functional groups present in the substance. For this purpose, 
fourteen FT-IR tests were done by mixing each drug entities separately with the individual 
excipient in the ratio of 1:1 along with separate tests of pure sample of rosuvastatin and 
amlodipine. The IR spectrum exhibiting the transmittance of different functional groups of the 
pure sample of rosuvastatin and amlodipine within 4000-400cm-1 region were checked, studied 
& recorded and their comparison had been done with the  IR spectrum exhibiting transmittance 
of those same functional groups in presence of all the excipients individually. If the expressions 
of the functional groups of the pure drug entities come in similar pattern in presence of excipient 
as in the pure sample, the drug can be claimed compatible in presence of excipient. The tests 
were designed in 1:1 ratio as follows: 
1. Rosuvastatin calcium (standard) 
2. Rosuvastatin calcium + Pregelatinized starch 
3. Rosuvastatin calcium + Microcrystalline cellulose 
4. Rosuvastatin calcium + Sodium starch glycolate 
5. Rosuvastatin calcium + Colloidal Sillicon dioxide 
6. Rosuvastatin calcium + Butylated hydroxyanisole  
7. Rosuvastatin calcium +Magnesium stearate 
8. Amlodipine besylate (standard) 
9. Amlodipine besylate + Pregelatinized starch 
10. Amlodipine besylate + Microcrystalline cellulose 
11. Amlodipine besylate + Sodium starch glycolate 
12. Amlodipine besylate + Colloidal Sillicon dioxide  
13. Amlodipine besylate + Butylated hydroxyanisole 
14. Amlodipine besylate + Magnesium stearate 
Preparation of samples for FT-IR: 
1. Rosuvastatin calcium (standard) 
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Appropriate quantity of potassium bromide (KBr) and rosuvastatin calcium standard (100:1) 
were mixed by grinding in an agate mortar. Pellets were made with about 100 mg mixture and 
the FT-IR spectra were recorded with FT-IR 8400 Fourier transform Infrared spectrophotometer, 
Shimadzu in the range of 4000-400 cm-1. 
2. Rosuvastatin calcium + Pregelatinized starch: 
Appropriate quantity of potassium bromide (KBr), rosuvastatin calcium standard and 
pregelatinized modified starch (100:1:1) were mixed by grinding in an agate mortar. Pellets were 
made with about 100 mg mixture and the FT-IR spectra were recorded with FT-IR 8400 Fourier 
transform infrared spectrophotometer, Shimadzu in the range of 4000-400 cm-1. 
3. Rosuvastatin calcium + Microcrystalline cellulose: 
Appropriate quantity of potassium bromide (KBr), rosuvastatin calcium standard and 
microcrystalline cellulose (100:1:1) were mixed by grinding in an agate mortar. Pellets were 
made with about 100 mg mixture and the FT-IR spectra were recorded with FT-IR 8400 Fourier 
transform infrared spectrophotometer, Shimadzu in the range of 4000-400 cm-1.  
4. Rosuvastatin calcium + Sodium starch glycolate: 
Appropriate quantity of potassium bromide (KBr), rosuvastatin calcium standard and sodium 
starch glycolate (100:1:1) were mixed by grinding in an agate mortar. Pellets were made with 
about 100 mg mixture and the FT-IR spectra were recorded with FT-IR 8400 Fourier transform 
infrared spectrophotometer, Shimadzu in the range of 4000-400 cm-1. 
5. Rosuvastatin calcium + Colloidal Sillicon dioxide: 
Appropriate quantity of KBr potassium bromide (KBr), rosuvastatin calcium standard and 
colloidal sillicon dioxide (100:1:1) were mixed by grinding in an agate mortar. Pellets were 
made with about 100 mg mixture and the, FT-IR spectra were recorded with FT-IR 8400 Fourier 
transform infrared spectrophotometer, Shimadzu in the range of 4000-400 cm-1.  
6. Rosuvastatin calcium + Butylated hydroxyanisole:  
Appropriate quantity of potassium bromide (KBr), rosuvastatin calcium standard and butylated 
hydroxyanisole (100:1:1) were mixed by grinding in an agate mortar. Pellets were made with 
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about 100 mg mixture and the FT-IR spectra were recorded with FT-IR 8400 Fourier transform 
infrared spectrophotometer, Shimadzu in the range of 4000-400 cm-1.  
7. Rosuvastatin calcium + Magnesium stearate: 
Appropriate quantity of potassium bromide (KBr), rosuvastatin calcium standard and 
Magnesium stearate (100:1:1) were mixed by grinding in an agate mortar. Pellets were made 
with about 100 mg mixture and the FT-IR spectra were recorded with FT-IR 8400 Fourier 
transform infrared spectrophotometer, Shimadzu in the range of 4000-400 cm-1.  
8. Amlodipine besylate (standard): 
Appropriate quantity of potassium bromide (KBr) and amlodipine besylate standard (100:1) were 
mixed by grinding in an agate mortar. Pellets were made with about 100 mg mixture and the FT-
IR spectra were recorded with FT-IR 8400 Fourier transform Infrared spectrophotometer, 
Shimadzu in the range of 4000-400 cm-1. 
9. Amlodipine besylate   + Pregelatinized starch: 
Appropriate quantity of KBr (Potassium bromide), amlodipine besylate standard and 
pregelatinized starch (100:1:1) were mixed by grinding in an agate mortar. Pellets were made 
with about 100 mg mixture and the FT-IR spectra were recorded with FT-IR 8400 Fourier 
transform infrared spectrophotometer, Shimadzu in the range of 4000-400 cm-1.  
10. Amlodipine besylate + Microcrystalline cellulose: 
Appropriate quantity of potassium bromide (KBr), amlodipine besylate standard and 
microcrystalline cellulose (100:1:1) were mixed by grinding in an agate mortar. Pellets were 
made with about 100 mg mixture and the FT-IR spectra were recorded with FT-IR 8400 Fourier 
transform infrared spectrophotometer, Shimadzu in the range of 4000-400 cm-1.  
11. Amlodipine besylate + Sodium starch glycolate:  
Appropriate quantity of potassium bromide (KBr), amlodipine besylate standard and sodium 
starch glycolate (100:1:1) were mixed by grinding in an agate mortar. Pellets were made with 
about 100 mg mixture and the FT-IR spectra were recorded with FT-IR 8400 Fourier transform 
infrared spectrophotometer, Shimadzu in the range of 4000-400 cm-1.  
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12. Amlodipine besylate + Colloidal Sillicon dioxide : 
Appropriate quantity of potassium bromide (KBr), amlodipine besylate standard and colloidal 
sillicon dioxide (100:1:1) were mixed by grinding in an agate mortar. Pellets were made with 
about 100 mg mixture and the FT-IR spectra were recorded with FT-IR 8400 Fourier transform 
infrared spectrophotometer, Shimadzu in the range of 4000-400 cm-1.  
13. Amlodipine besylate + Butylated hydroxyanisole: 
Appropriate quantity of potassium bromide (KBr), amlodipine besylate standard and butylated 
hydroxyanisole (in the ratio 100:1:1) were mixed by grinding in an agate mortar. Pellets were 
made with about 100 mg mixture and the FT-IR spectra were recorded with FT-IR 8400 Fourier 
transform infrared spectrophotometer, Shimadzu in the range of 4000-400 cm-1.  
14. Amlodipine besylate + Magnesium stearate: 
Appropriate quantity of potassium bromide (KBr), amlodipine besylate standard and Magnesium 
stearate (100:1:1) were mixed by grinding in an agate mortar. Pellets were made with about 100 
mg mixture and the FT-IR spectra were recorded with FT-IR 8400 Fourier transform infrared 
spectrophotometer, Shimadzu in the range of 4000-400 cm-1. 
2.2.   Method development & validation 
A method should be developed with a goal to rapidly test preclinical samples, formulation 
prototypes, and commercial samples (Breaux et al., 2003).The Good Quality Control Laboratory 
Practice (GQCLP) requires test methods to assess the compliance of pharmaceutical product with 
established specification and to meet proper standard of accuracy and reliability. The validated 
method will give consistent and reliable results which are mainly concerned with source of errors 
and their estimation in the experiment. If the estimated errors are within the acceptable limit, 
then the method is said to be validated and qualified for its intended use.  
For good quality control laboratory practice, numerous methods need to be developed to 
ascertain the identity, claimed potency, strength, quality and purity of different drug substance 
and drug product. These physicochemical properties of any drug substance or others are checked 
through different test methods such as assay test, content uniformity test, 
dissolution/disintegration tests, and moisture quantity test etc. These test methods vary from one 
API to another. Therefore, before manufacturing or launching any new product to the market, 
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different test methods specific to the product need to be fixed initially so that the 
physicochemical properties of that drug product could be checked whenever needed to ensure the 
safety and efficacy throughout the shelf life including storage, distribution and use (Patil et al., 
2001). 
In the present study a simple, sensitive and reproducible analytical assay method with better 
detection range for the estimation of rosuvastatin & amlodipine in pure form and in its 
pharmaceutical dosage forms was developed and validated. Based on the developed and 
validated RP-HPLC (appendix 6) method for the assay studies, the method was further used to 
evaluate the in vitro dissolution study (appendix 7) of the formulated dosage form and its 
comparison had been done with the separate market preparations of rosuvastatin and amlodipine 
since combined formulation of them is not currently available in the market. For this purpose, 
pure sample of rosuvastatin & amlodipine, available market tablets of rosuvastatin and 
amlodipine and the combination formulation (proposed) of rosuvastatin and amlodipine (CF-RA) 
were collected in the initial phase of the study to develop the intended assay method by using 
RP-HPLC. A system of documentation relating to the study was also recorded & maintained 
from the very beginning of the study. The chemical used as reagents and the apparatus used for 
the studies have been listed below (Table 2 and Table 3): 
 
 
Table 2: List of chemicals used 
Name Manufacturer 
Acetonitrile 
Active Fine Chemicals Ltd, 
Bangladesh 
Potassium Dihydrogen 
Phosphate 
Scarlab, Spain 
Orthophosphoric Acid 
ACI Labscan, RCI Labscan limited, 
Thailand. 
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Table 3: List of apparatus used 
Name Manufacturer Model 
Electronic Balance Shimadzu, Japan ATY-224 
Ultrasonic water bath Lab Tech, Korea LUC-405 
High Pressure Liquid 
Chromatography 
(HPLC) 
Shimadzu, Japan Prominence 
 
Some random steps taken during method development of the combined formulation of 
rosuvastatin and amlodipine are been discussed below: 
A. Separation technique: 
Separation of rosuvastatin and amlodipine out of any sample prior to its quantitative or 
qualitative analysis is essential and this separation should be within the acceptable range. 
Therefore, to determine whether that separation is optimum for any particular study, some 
criteria along with its acceptable ranges had been set which may differ according to instrument 
type, detector, column type, dimensions, and alternative column, filter type, etc. In the present 
study, separation of the API has been done by HPLC.  Some recommended criteria’s with their 
acceptable separation range have been given below (Table 4). 
B. Solution preparation: 
To prepare solution of standards and samples of rosuvastatin and amlodipine for separation and 
identification the following factors were considered and documented: 
a. Weighing of optimum amount of sample. 
b. Requirement for dilution or buffering of solution. 
c. The compatibility of diluents with the mobile phase for better baseline peak. 
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Table 4: Separation Criteria 
Criteria Comment 
Resolution 
Precise and rugged quantitative analysis requires that resolution 
must be greater than 1.5. 
Separation time 
<5-10 minutes is desirable for routine procedure (e.g. 
dissolution profile). 
Quantification <2% RSD for assays. 
Pump pressure 
<150 bar is desirable. <200 bar is usually essential (for UPLC – 
water and RRLC-agilent these values are 5 fold and 3 fold 
respectively). 
Peak height Narrows peaks are desirable for large signal/noise ratio. 
Solvent consumption Minimum mobile phase use per run is desirable. 
C. Instrumental setup and separation condition: 
a. The installation and operational performance of instrumentation was structured according 
to the laboratory standard operating procedures (SOP).  
b. Before the initiation of methodology development in HPLC completely new column, 
solvent, diluents, filter and syringe were used in order to avoid any error which may stall 
the accuracy of result obtained.  
c. Analysis was done using analytical condition described in secondary literatures. The 
method sensitivity requirements for a proposed new method are influenced by several 
factors. These include the instrument detection limits, method quantification limits, and 
the regulatory requirements for the proposed applications (RCRA program). 
d. The important criteria considered for method development are resolution, sensitivity, 
precision, accuracy, limit of detection, limit of quantification, linearity, reproducibility, 
and time of analysis and robustness of the method. In all of these, the column quality 
plays an important role since the peak shape affects all criteria required for optimum 
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separation. Column dimensions and particle size affect the speed of analysis, resolution, 
column backpressure, detection limit, and solvent consumption. 
e. Chromatography also requires a proper balance of the intermolecular forces between the 
analyte, the mobile phase, and the stationary phase for effective analysis. 
During the HPLC/UPLC method development, the first sample was injected to assure that the 
selected wavelength will sense all sample components of interest (Snyder et al., 2012). Normally 
variable wavelength UV detector is the first choice of the chromatographers, because of their 
convenience and applicability for most organic samples. Here, in the study, UV spectra were 
obtained by PDA detector. 
Due to the relatively nonpolar properties of amlodipine and rosuvastatin, a reversed phase HPLC 
system was used to analyze both compounds with a sufficient separation and fine peak shapes. 
Therefore, all the experiments were carried out on a Luna 5µ C18 column (250 mm x 4.60 mm) 
using different conditions of various mobile phases systematically. 
D. Choice of Method: 
For the estimation method of rosuvastatin and amlodipine, methods from various papers were 
reviewed and the preferable methodology was eventually adopted and modified after undertaking 
several trial and error steps. The mobile phase systems that were initially fixed focusing on the 
gradient elution of rosuvastatin and amlodipine are as follows: 
i. Phosphate buffer (pH 2.5): Acetonitrile in the ratio 55:45 % v/v 
ii. Acetonitrile: THF: water at pH 3 in the ratio 68:12:20 % v/v 
E. Optimization: 
After determining that the chosen analytical approach would work for its intended application 
with appropriate sensitivity, the general procedure is to optimize the method. During 
optimization one parameter is changed at a time and other conditions are isolated. The initial 
parameters are chosen according to the analyst's best judgment. These are then varied 
systematically to obtain the greatest response, least interference, greatest repeatability, etc. 
Developers must determine those variables which should not be changed without adversely 
affecting method performance (RCRA Program). Accordingly, documentation was done for each 
and every step. 
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According to (Tajane et al, 2012), the ratio of the mobile phase (Acetonitrile: THF: water at pH 3 
in the ratio 68:12:20 % v/v) gave the most optimum response with least interference. Therefore, 
at the initial point of the study, for the selection of mobile phase, the various compositions of 
mobile phase verification were carried out based on the study by Tajane et al. for the gradient 
elution of rosuvastatin and amlodipine are mentioned as follows: 
MP (1) - acetonitrile: THF: water pH 3 (68:12:20 % v/v) 
MP (2) - acetonitrile: THF: water pH 3 (48:12:40 % v/v) 
MP (3) - acetonitrile: THF: water pH 3 (38:12:50 % v/v) 
MP (4) - acetonitrile: THF: water pH 3 (78:12:10 % v/v) 
MP (5) - acetonitrile: THF: water pH 3 (58:12:30 % v/v) 
MP (6) - acetonitrile: THF: water pH 3 (48:22:30 % v/v) 
MP (7) - acetonitrile: THF: water pH 3 (53:17:30 % v/v) 
MP (8) - acetonitrile: THF: water pH 3.5 (50:10:40 % v/v) 
MP (9) - acetonitrile: THF: water pH 4 (50:10: 40 % v/v) 
MP (10) - acetonitrile: THF: water pH 3 (50:10:40 % v/v) 
At the initial phase of the study mobile phase containing acetonitrile: THF: water pH 3.5 in 
(50:10:40 % v/v) had been selected to conduct the study as it gave sharp, completely resolved 
peak of standard rosuvastatin and amlodipine but when the dissolution profile of market 
preparation of rosuvastatin was studied, the chromatogram of rosuvastatin and its symmetry were 
found to be unacceptable. This was one of the reasons why this particular mobile phase system 
was discarded, the other reason being the toxicity of THF and their detrimental effect after its 
disposal to the environment. Therefore, based on several considerations, the mobile phase 
containing acetonitrile and phosphate buffer was finally selected in the ratio of 45% and 55% 
respectively since it was found to give the best resolution for both the drugs. 
Moreover, the sensitivity of HPLC that uses UV detection depends upon the proper selection of 
detection wavelength. An ideal wavelength is one that gives good response for the drugs that are 
to be detected. For good detection, optimization of wavelength was done at different wavelength 
by preparing 10µg/ml of RSV and 5µg/ml of AML. The suitable wavelength for detection of 
rosuvastatin calcium and amlodipine besylate was selected from the overlain spectrum of 
rosuvastatin and amlodipine and the selected wavelength was 240 nm.  
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After the initial experiments, the optimum conditions (Table 5) were found to be the mobile 
phase of acetonitrile: phosphate buffer (pH 2.5) and (45:55) % v/v mixture pumped at 1.5 ml/min 
flow rate and 240 nm UV detection wavelength. Under the optimum conditions, amlodipine and 
rosuvastatin were eluted at 2.7 min and 6.08 min, respectively. 
F. Method Validation: 
Once a method is developed, it needs to be validated. Analytical method validation is a process 
of establishing documented evidence that provides a high degree of assurance that a specific 
method and the ancillary instruments included in the method will yield consistent results which 
accurately will reflect the quality of the product and reliability of the test. However, changes may 
occur which make it necessary to evaluate whether the method is still suitability for its intended 
use (McPolin, 2009). The change may be covered by the existing validation, in which case no 
further validation is required or the change my result in revalidation and in some cases 
redevelopment is required followed by validation of the new method (McPolin, 2009). This will 
also demonstrate in a laboratory study that the performance characteristics of a method of 
analysis make it fit for the intended analytical application. Methods should be validated to 
include consideration of characteristics included in the International Conference on 
Harmonization (ICH) guidelines addressing the validation of analytical methods (Step-by-Step 
Analytical Methods Validation). It specifies the type of tests required and the order in which the 
tests should be conducted.  
To outline the validation procedure of dissolution sample of combined formulation of 
rosuvastatin (10 mg) and amlodipine (5 mg) the following validation parameters was studied- 
 System suitability test 
 Accuracy 
 Precision 
 Linearity and range 
 Limit of Quatitation 
 Limit of detection 
 Robustness 
 Ruggedness 
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Table 5: Specified Chromatographic condition for assay method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G. Preparation of Solutions: 
a) Preparation of Buffer:   
About 4.0827 gm of potassium dihydrogen phosphate was dissolved in 900 ml of distilled water 
and the pH adjusted at 2.5 by orthosphosphoric acid. The volume was then made up to 1000 ml. 
b) Preparation of Mobile Phase:   
Phosphate buffer solution of pH 2.5 was mixed with acetonitrile at a ratio of 55:45. It was 
filtered using the filter pore size not greater than 0.45 µm. Finally the mixture was degassed in an 
ultrasonic bath.   
c) Preparation of Diluents : 
Mobile phase was used as diluents. 
Chromatographic Mode Chromatographic condition 
Mobile phase Acetonitrile : Phosphate buffer = (45: 55) % v/v 
Stationary phase Luna 5µ C18 column (250 mm x 4.60 mm) 
Temperature ambient 
Sample size 10µl 
Flow rate 1.5 ml/min 
Detection wavelength 240 nm 
Total run time 8 min (approximately) 
Retention time 
Rosuvastatin calcium: 
Approximately 6.08 mins 
Amlodipine besylate:  
Approximately 2.7 min 
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d) Standard Preparation:                                                                              
Standard stock solution of rosuvastatin and amlodipine was prepared by dissolving 25 mg 
rosuvastatin calcium and 12.5 mg amlodipine besylate respectively with a small quantity of 
mobile phase into a clean dry 100 ml volumetric flask. It was then sonicated for 20 min and the 
final volume of the solution was then made up to 100 ml with mobile phase. 4 ml solution was 
taken into 100 ml volumetric flask to obtain a concentration of 10 µg/ml rosuvastatin and 5 µg/ml 
amlodipine.  
e) Sample preparation: 
A total of 20 tablets were accurately weighed and powdered in a clean dry mortar. An amount 
equivalent to 10 mg of rosuvastatin and 5 mg of amlodipine was taken conical flask and 
solubilised in small quantity mobile phase with the aid of ultrasonication for 15 min. The 
resultant solution was then filtered through WHATMAN filter paper into a clean dry 100 ml 
volumetric flask and finally the volume was make upto 100 ml with mobile phase. From the 
solution, 1 ml was taken out into 10 ml volumetric flask and dilution was done with mobile 
phase to get a concentration of 10 µg/ml rosuvastatin and 5 µg/ml amlodipine. From this solution 
further dilutions were done and were injected into the system to get the chromatogram. 
2.3. In­vitro Dissolution study 
Dissolution test is generally required to evaluate the release of drug from pharmaceutical dosage 
form as a predictor of the in vivo performance of a drug product. For the evaluation of 
dissolution of combined formulation of rosuvastatin calcium and amlodipine besylate, different 
dissolution media has been used to ascertain their percentage of release according to the 
respective dissolution profile in FDA.  
 Dissolution of Rosuvastatin: 
Dissolution study of rosuvastatin was done using dissolution apparatus II (Paddle) at 50 rpm in 
0.05 M sodium citrate buffer of pH 6.6 at temperature (37 ± 0.5)°C for 60 minutes. 
Preparation of 0.05 M Sodium citrate buffer: 
14.7 gm of trisodium citrate dehydrate and 0.65 gm citric acid monohydrate was dissolved in 1 L 
distilled water & pH was adjusted to 6.6 using 1 M NaOH or 1 M HCl. 
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Preparation of standard: 
25 mg rosuvastatin of working standard was accurately weighed & transferred into a clean & dry 
100 ml volumetric flask. 50 ml dissolution media was added to it and shacked vigorously for 5 
minutes. If necessary, for the next few minutes sonication was done. Its volume was then 
adjusted up to the mark and allowed to cool in room temperature. This is solution A.  
4 ml solution was taken from solution A into a clean and dry 100 ml volumetric flask and 50 ml 
dissolution media was added to it and shacked vigorously. Its volume was then adjusted up to the 
marks with the dissolution media. This is solution B. The solution was filtered through 0.2µ disk 
filter and vial was prepared. 
Preparation of sample: 
900 ml dissolution medium 0.05 M sodium citrate was poured into the dissolution vessels. Then 
the media was warmed to a temperature of 37 ± 0.5°C. Three tablets of CF-RA (containing 10 
mg rosuvastatin and 5 mg amlodipine) and three tablets of rosuvastatin available at market (top 
brands in the local market) were weighed and immersed into the media, one tablet on each vessel 
between the paddle and the bottom. The apparatus was operated at 50 rpm for 60 min. Samples 
of about 10 ml had been withdrawn after 10, 20, 30, 45 and 60 min. Afterwards they were 
filtered through Whatman filter paper or with other equivalent filter. The filtrates were then 
finally filtered through 0.2µ disk filter and vials were prepared. 
Procedure: 
The vials containing standard and sample, both in concentrations of 10 µg/ml were then placed 
into the tray of auto sampler of Shimadzu HPLC and they were injected under the following 
chromatographic conditions. 
Chromatographic system: 
a) Apparatus: Shimadzu HPLC-prominence integrated with PDA detector 
b) Column: Luna 5µ C18 column (250 mm x 4.60 mm) 
c) Mobile phase: Acetonitrile : phosphate buffer = 45:55 
d) Temperature: Ambient 
e) Flow rate: 1.5 ml/min 
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f) Load: 10 µl 
g) Retention time: 6.08 min (approx) 
h) Run time: 8 min (approx) 
i) Wavelength: 240 nm 
 Dissolution of amlodipine: 
Dissolution study of Amlodipine was done using dissolution apparatus II (paddle) at 75 rpm in 
0.01 N HCl at temperature (37 ± 0.5)°C for 60 minutes.  
Preparation of 0.01 N HCL: 
0.825 ml 0.01 N HCl was dissolved in 1 L distilled water and pH was adjusted to 2.5 using 1 M 
HCl. 
Preparation of standard: 
25 mg amlodipine of working standard was accurately weighed & transferred into a clean & dry 
100 ml volumetric flask. 50 ml dissolution media was added to it and shacked vigorously for 5 
minutes. If necessary, for next the few minutes sonication was done. Its volume was then 
adjusted up to the mark and allowed to cool in room temperature. This is solution A.  
4 ml from solution A was taken into a clean and dry 100 ml volumetric flask and 50 ml 
dissolution media was added to it and shacked vigorously. Its volume was then adjusted up to the 
mark with the dissolution media. This is solution B. Finally, the solution was filtered through 
0.2µ disk filter and vial was prepared. 
Preparation of sample: 
500 ml medium 0.01 N HCl was poured into the dissolution vessels. Then the media was 
warmed to a temperature of 37 ± 0.5°C. Three tablets of CF-RA (containing 10 mg rosuvastatin 
and 5 mg amlodipine) and three tablets of amlodipine available at market (top brands in the local 
market) were weighed and immersed into the media, one tablet on each vessel between the 
paddle and the bottom. The apparatus was operated at 75 rpm for 60 min. Sample of about 10 ml 
had been withdrawn after 10, 20, 30, 45 and 60 min. Afterwards they were filtered through 
Whatman filter paper or with other equivalent filter. The filtrates were then finally filtered 
through 0.2µ disk filter and vials were prepared. 
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Procedure:  
The vials containing standard and sample, both in concentrations of 10 µg/ml, were then placed 
into the tray of auto sampler of Shimadzu HPLC and they were injected into the system under 
the following chromatographic conditions. 
Chromatographic system: 
a) Apparatus: Shimadzu HPLC-prominence integrated with PDA detector 
b) Column: Luna 5µ C18 column (250 mm x 4.60 mm) 
c) Mobile phase: Acetonitrile : phosphate buffer = 45:55 
d) Temperature: Ambient 
e) Flow rate: 1.5 ml/min 
f) Load: 10 µl 
g) Retention time: 2.8 min (approx) 
h) Run time: 8 min (approx) 
i) Wavelength: 240 nm 
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Chapter 3 
Data Analysis 
3.1. FT-IR study 
In the study, FT-IR 8400 Fourier transform infrared spectrophotometer was employed for 
ascertaining the compatibility of the excipient with the API through comparative qualitative 
analysis of the different functional groups of pure sample of rosuvastatin calcium (Figure 3) and 
amlodipine besylate (Figure 4) as well as mixed sample of those drug entities separately with all 
the excipients individually (Figures 5-18). The results of the study are shown below in Table 6 
and Table 7. 
 
 
 
Figure 3: Structure of Rosuvastatin calcium 
 
 
 
 
 
 
 
Figure 4: Structure of Amlodipine besylate 
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Table 6: FT-IR Study of rosuvastatin calcium (standard) and its comparison with the mixed sample of rosuvastatin calcium and 
individual excipients 
 
O-H stretching 
ALCOHOL 
Broad & strong 
3550-3200 
Dual Response 
3300-2500 
O-H stretching 
Carboxylic acid 
3200-2700 
O-H stretching 
Alcohol 
(intramolecular bonded) 
S=O 
stretching 
SULFONE 
Strong 
1160-1120 
 
 
Remarks 
Rosuvastatin calcium (standard) 3420.87 2969.55 2928.04 1156.36  
RSV + pregelatinized modified starch 3420.87 2968.55 2931.90 1155.40 Compatible 
 RSV + microcrystalline cellulose 3420.87 2966.62 2930.93 1156.36 Compatible 
 RSV + Sodium starch glycolate 3440.16 2968.55 2930.93 1155.40 Compatible 
Due to the presence of huge number of –OH group in Starch molecule, 
they together with –OH group of RSV have given common broaded 
response near 3400 cm-1 region. So, the position of the peak of –OH group 
is slightly diverted. 
RSV + Colloidal SiO2 3433.41 2969.51 2934.79 1113.93 Compatible 
The sulfone group gave out a merged peak with Si=O near to 1111 cm-1 
region which is broaded. So the position of the peak got diverted. 
 RSV + Butylated hydroxyanisole 3421.83 2952.15 2915.5 1156.36 Compatible 
RSV + Magnesium stearate There was a possibility of 
peak but the instrument 
printed out the default one 
2956.97 2916.47 1156.36 Compatible 
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Table 7: FT-IR Study of amlodipine besylate (standard) and its comparison with the mixed sample of amlodipine besylate and 
individual excipient 
 
N-H 
stretching 
Medium 
Primary 
Amine 
3330-3250 
N-H stretching 
Medium 
Secondary 
Amine 
3350-3310 
C-H stretching 
Strong 
Alkene 
3100-3000 
C=O 
stretching 
Strong 
α,β- 
unsaturated 
ester 
1730-1715 
S=O 
Stretching 
Strong 
Sulfone 
1160-1120 
 
 
Remarks 
Amlodipine besylate 
(standard) 
3300.31 3157.58 3069.81 1696.45 1125.5 Compatible 
AMD besylate  + 
pregelatinized modified 
starch 
3285.85 3155.65 3066.92 1696.45 1125.5 Compatible 
AMD besylate 
+ Microcrystalline cellulose 
3420.91 3169.15 
Due to instrumental error the response 
of alkene cannot get detected. The 
pattern near 3000 cm-1 show there is a 
possibility of alkene response. 
1696.45 1125.5 
Compatible 
Due to the presence of huge number of –OH 
group,they together with the N-H group has 
given common broaded peak near 3300-
3500 cm-1 region. So, the position of the 
peak of N-H is slightly diverted 
AMD besylate 
+ 
Sodium starch glycolate 
3291.63 3155.65 3083.31 1696.45 1125.50 Compatible 
AMD besylate 
+ 
Colloidal SiO2 
The 
instrument 
printed out the 
default one, 
but there is a 
peak of 
similar pattern 
near 3300 cm-
1 region 
The instrument 
printed out the 
default one, but 
there is a peak 
of similar 
pattern near 
3155 cm-1 
region 
The instrument printed out the default 
one, but there is a peak of similar 
pattern near 3085 cm-1 region 
1696.45 1125.5 
Compatible 
For the conduction of experiment using FT-
IR, the default mode of the IR- spectrum got 
printed. Still the spectrum has shown the 
possible response of the desired functional 
group. 
AMD. besylate + Butylated 
hydroxyanisole 
3329.25 3154.68 3068.85 1696.45 1125.5 Compatible 
AMD besylate + Mg 
stearate 
3292.60 3164.33 3066.92 1696.45 1125.50 Compatible 
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Figure 5: FT-IR study of Rosuvastatin calcium standard 
 
Figure 6: FT-IR study of Rosuvastatin calcium and pregelatized starch mixture (1:1) 
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Figure 7: FT-IR study of rosuvastatin calcium and microcrystalline cellulose mixture (1:1) 
 
Figure 8: FT-IR study of rosuvastatin calcium and Sodium starch glycolate mixture (1:1) 
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Figure 9: FT-IR study of rosuvastatin calcium and colloidal sillicon dioxide mixture (1:1) 
 
Figure 10: FT-IR study of Rosuvastatin calcium and butylated hydroxyanisole (1:1) 
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Figure 11: FT-IR study of Rosuvastatin calcium and Magnesium stearate (1:1) 
 
Figure 12: FT-IR study of Amlodipine besylate standard 
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Figure 13: FT-IR study of Amlodipine besylate and pregelatized starch mixture (1:1) 
 
Figure 14: FT-IR study of Amlodipine besylate and microcrystalline cellulose mixture (1:1) 
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Figure 15: FT-IR study of Amlodipine besylate and Sodium starch glycolate mixture (1:1) 
 
Figure 16: FT-IR study of Amlodipine besylate and colloidal sillicon dioxide mixture (1:1) 
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Figure 17: FT-IR study of Amlodipine besylate and butylated hydroxyanisole (1:1) 
 
 
Figure 18: FT-IR study of Amlodipine besylate and Magnesium stearate (1:1) 
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3.2. Validation parameters for assay study 
3.2.1. System Suitability Test 
A suitability test was applied to the chromatograms of taken under optimum conditions to check 
various parameters such as column efficiency (theoretical plates), peak tailing, retention factor, 
and resolution (Celebier et al., 2010). Freshly prepared standard stock solution of rosuvastatin 
and amlodipine were injected into the chromatographic system (Figure 19) under the optimized 
chromatographic conditions (Patil et al., 2001). The test is considered valid if the following two 
considerations are met: 
• The relative standard deviation for the peak area response of rosuvastatin and amlodipine for 
replicate injections of standard preparation is not more than 2% respectively (Qiu et al., 
2009) 
• Tailing factor: ≤ 2% for the rosuvastatin and amlodipine peak in standard solution. 
 
 
 
Figure 19:  Chromatogram of standard Rosuvastatin calcium and amlodipine besylate  
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Table 8: System suitability parameters of Standard Rosuvastatin calcium 
Rosuvastatin calcium 
Tailing factor Theoretical plate Peak area Retention time 
1 1.165 6330 140745 6.185 
2 1.163 6432 140724 6.182 
3 1.123 6345 140765 6.194 
4. 1.143 6349 140754 6.186 
5. 1.156 6354 140798 6.18 
6. 1.165 6343 140812 6.192 
Average 1.153 6359 140766 6.187 
STD 0.017 36.73 33.13 0.006 
RSD (%) 1.45 0.578 0.024 0.089 
 
Table 9: System suitability parameters of Standard Amlodipine besylate 
Amlodipine besylate 
Tailing factor Theoretical plate Peak area Retention time 
1 1.032 10751 159936 2.595 
2 1.032 10702 160552 2.59 
3 1.037 10754 160915 2.596 
4. 1.039 10736 160468 2.593 
5. 1.036 10745 160432 2.595 
6. 1.033 10732 160443 2.594 
Average 1.035 10737 160458 2.594 
STD 0.003 18.97 313.42 0.002 
RSD (%) 0.28 0.177 0.195 0.082 
Data interpretation: 
It is observed from the above tabulated data (Table 8 and Table 9) that the method complies with 
the system suitability parameters. Hence, it can be concluded that the system suitability 
parameters meets the requirement of method validation. 
3.2.2. Linearity 
Linearity is typically established by preparing solutions of the drug substance, ranging in 
concentration from less than the lowest expected concentration to more than the highest 
concentration during release (The Dissolution Procedure: Development and Validation, 2014). 
Procedure: 
 Samples at concentrations 80%, 90%, 100%, 110%, and 120% of the target concentration 
were prepared and were injected into the chromatographic condition. 
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 Chromatograms were taken and concentration of samples versus corresponding peak area 
was plotted (Table 10 and 11) to get a calibration curve (Figure 20 and 21). From the data 
obtained, co-relation coefficient, slope and y-intercept were calculated. Ideally, co-relation 
coefficient should be around 1. 
Preparation of linearity samples: 
Samples of different concentrations required for linearity test were prepared as follows: 
• 80% solution: 
 0.32 ml solution was taken from the stock solution in a 10 ml volumetric flask and volume was 
made up to 10 ml using mobile phase mixture. 
• 90% solution: 
0.36 ml solution was taken from stock solution in a 10 ml volumetric flask and volume was 
made up to 10 ml using mobile phase mixture. 
• 100% solution: 
0.4 ml solution was taken from stock solution in a 10 ml volumetric flaskand volume was made 
up to 10 ml using mobile phase mixture. 
• 110% solution: 
0.44 ml solution was taken from stock solution in a 10 ml volumetric flask and volume was 
made up to 10 ml using mobile phase mixture. 
• 120% solution: 
0.48 ml solution was taken from stock solution in a 10 ml volumetric flask and volume was 
made up to 10 ml using mobile phase mixture. 
 
 
 
 
Data Analysis 
39 
 
Table 10: Result of Linearity study of Rosuvastatin calcium 
Rosuvastatin calcium 
Concentration (mg/ml) Peak Area 
1. 0.008 125146.6 
2. 0.009 143739.2 
3. 0.01 162706.2 
4. 0.011 173612.6 
5. 0.012 191398 
 
Table 11: Result of Linearity study of Amlodipine besylate 
Amlodipine besylate 
Concentration (mg/ml) Peak Area 
1. 0.004 50972 
2. 0.0045 57631 
3. 0.005 64984 
4. 0.0055 69629.4 
5. 0.006 76380.6 
 
 
Figure 20: Linearity curve of Rosuvastatin calcium 
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Figure 21: Linearity curve of Amlodipine besylate 
Data Interpretation:  
The method was found to be linear with the 4 µg/ml to 6 µg/ml concentration of amlodipine and 
8 µg/ml to 1.2 µg/ml concentration of rosuvastatin. The co-relation coefficient was found to be 
0.992 for Rosuvastatin and 0.995 for amlodipine. 
3.2.3. Accuracy 
The accuracy of the assay method was evaluated with the recovery of the standards from 
excipients (Tajane et al., 2012). Accuracy/recovery are typically established by preparing 
multiple samples containing the drug and any other constituents present in the dosage form 
ranging in concentration from below the lowest expected concentration to above the highest 
concentration during release. For this purpose, accuracy must be done on at least 3 
concentrations (80%, 100% and 120%) in the expected range. 
Preparation of accuracy sample: 
Samples of different concentrations required for accuracy test were prepared as follows: 
• 80% solution: 
3.2 ml solution was taken from the stock solution in a 10 ml volumetric flask which was 
previously filled with 17.5 mg placebo. The volume was made up to 10 ml using mobile phase 
mixture (Figure 22).  
Data Analysis 
41 
 
• 100% solution: 
4 ml solution was taken from the stock solution in a 10 ml volumetric flask which was 
previously filled with 14 mg placebo. The volume was made up to 10 ml using mobile phase 
mixture (Figure 23).  
• 120% solution: 
4.8 ml solution was taken from the stock solution in a 10 ml volumetric flask which was 
previously filled with 21 mg placebo. The volume was made up to 10 ml using mobile phase 
mixture (Figure 24).  
 
Figure 22: Chromatogram of 80% solution (accuracy) 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Chromatogram of 100% solution (accuracy)  
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Figure 24: Chromatogram of 120% solution (accuracy) 
 
Table 12: Result of Accuracy study of rosuvastatin calcium and amlodipine besylate 
Accuracy 
 Rosuvastatin calcium Amlodipine besylate 
Sample 
no. 
Spike level 
(percentage) 
Percent (%) 
of recovery 
Mean percent 
(%) of recovery 
Spike level 
(percentage) 
Percent (%) 
of recovery 
Mean percent 
(%) of 
recovery 
1.  80% 99.01% 99.03% 80% 102.85% 102.88% 
2.  80% 99.05% 80% 102.90% 
3.  80% 99.03% 80% 102.89% 
4.  100% 101.91% 101.9% 100% 101.86% 101.97% 
5.  100% 101.89% 100% 102.09% 
6.  100% 101.90% 100% 101.97% 
7.  120% 102.04% 102.04% 120% 98.74% 98.67% 
8.  120% 102.05% 120% 98.60% 
9.  120% 102.04% 120% 98.69% 
 
Data Interpretation: 
The result of analysis (Table 12) showed excellent recoveries for both the drugs ranging from 98 
% to 102% for amlodipine & rosuvastatin which suggests the accuracy of the method for the 
simultaneous estimation of rosuvastatin and amlodipine. 
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3.2.4. Precision 
The precision was studied in terms of changes in peak area of standard and/or sample solution 
drug on the same day to evaluate the repeatability and on two different days over a period of one 
week to evaluate the reproducibility. The precision (percentage relative standard deviation, 
%RSD) was expressed with respect to the interday (Figure 26) and intra-day (Figure 27) 
variation in the expected drug concentration (Banerjee et al., 2013) and both the results have 
been compared with the standard stock solution (Figure 25). 
Preparation of precision sample: 
0.4 ml solution was taken from stock solution in a 10 ml volumetric flask and volume was made 
up to 10 ml using mobile phase mixture.  
 
Figure 25: Chromatogram of standard solution of rosuvastatin calcium and amlodipine besylate  
 
 
Figure 26: Chromatogram of standard solution of rosuvastatin calcium and amlodipine besylate 
(Interday) 
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Figure 27: Chromatogram of standard solution of rosuvastatin calcium and amlodipine besylate 
(Intraday) 
 
Table 13: Result of Precision study of rosuvastatin calcium and amlodipine besylate 
Injected 
no. 
Rosuvastatin Amlodipine 
Interday Intraday Interday Intraday 
Standard Sample Standard Sample Standard Sample Standard Sample 
1 161560 158933 163973 162000 64055 71861 65079 73119 
2 161428 159011 164267 162122 64203 71873 65029 73112 
3 161672 158852 163975 161721 64265 71518 65072 73337 
4 161567 158983 164448 161825 64275 71821 65027 73121 
5 161488 159269 164367 161773 64295 71847 65034 73051 
6 161504 158835 165454 161530 64278 71573 65077 73031 
Average 161536.5 158980.5 164414 161828.5 64228.5 71748.83 65053 73128.5 
Standard 
deviation 83.69 157.55 546.59 209.43 90.69 159.40 25.40 109.00 
%RSD 0.052 0.099 0.332 0.129 0.141 0.222 0.039 0.149 
 
Data interpretation: 
It is observed from the above tabulated data (Table.13) that the method is precise as the relative 
standard deviation of the sample and standard preparation of rosuvastatin and amlodipine is ≤ 
2%. 
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3.2.5. Ruggedness 
Ruggedness is a measure of reproducibility of test results under the variation in conditions 
normally expected from laboratory to laboratory and from analyst to analyst. To determine 
ruggedness of the proposed method, test sample solution was analyzed in five replicates 
comparing percentage relative standard deviation of the measurement of the two analysts in the 
same laboratory. 
Table 14: Result of Ruggedness study of rosuvastatin calcium and amlodipine besylate 
Analyst-1 Analyst -2 
Injected no 
Rosuvastatin 
Calcium 
(Peak Area) 
Amlodipine 
Besylate 
(Peak Area) 
Rosuvastatin 
Calcium 
(Peak Area) 
Amlodipine 
Besylate 
(Peak Area) 
1 160640 63482 160638 63472 
2 160496 63561 160399 63500 
3 160357 65404 160368 65358 
4 160399 63498 160456 63440 
5 160400 63874 160445 63456 
6 160193 63496 160333 63596 
Average 160414 63886 160440 63804 
Standard 
deviation 148.5 758.4 107.5 763.5 
%RSD 0.09 1.187 0.07 1.20 
 
Data interpretation: 
From the above data (Table 14)   it can be concluded that, the results are within the limit. 
Therefore, the method is rugged. 
3.2.6. Limit of Quantitation 
The limit of quantitation (LOQ) is defined as the lowest concentration of an analyte in a sample 
that can be quantitated. The quantitation limit is determined by the analysis of sample with 
known concentration of analyte and by establishing the minimum level at which the analyte can 
be reliably estimated with acceptable precision, accuracy under the stated experimental 
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conditions. The LOQ values were determined by formulae LOQ = 10 σ/m (where, σ is the 
standard deviation of the responses and m is the mean of the slope of the calibration curve).  
Table 15: Result of LOQ of rosuvastatin calcium and amlodipine besylate 
 
 
 
 
 
 
 
 
 
Figure 28: Chromatogram of LOQ study of rosuvastatin calcium (dilution 4) 
 
 
Figure 29: Chromatogram of LOQ study of amlodipine besylate (dilution 5) 
 Signal height Concentration (µg/ml) 
Rosuvastatin calcium 399 0.22 
Amlodipine besylate 401 0.095 
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 Dilution of rosuvastatin calcium: 
25 mg of rosuvastatin calcium was accurately weighed into 50 ml volumetric flask. The contents 
were dissolved using mobile phase, sonicated and the volume was made up to 50 ml with mobile 
phase mixture. This is the stock solution of rosuvastatin. 
Dilution 1 
22 ml of the stock solution of rosuvastatin calcium was taken in 100 ml volumetric flask and 
volume was made up to 100 ml with mobile phase mixture. This is solution A. 
Dilution 2 
2 ml of the solution form solution A was taken in 10 ml volumetric flask and volume was made 
up to 10 ml with mobile phase mixture. This is solution B. 
Dilution 3 
1 ml of the solution from solution B was taken in 10 ml volumetric flask and volume was made 
up to 10 ml with mobile phase mixture. This is solution C. 
Dilution 4 
1ml of the solution from solution C was taken in 10 ml volumetric flask and volume was made 
up to 10 ml with mobile phase. This is solution D (figure 28). 
 Dilution of Amlodipine besylate: 
12.5 mg of amlodipine besylate was accurately weighed into 100 ml volumetric flask. The 
contents were dissolved using mobile phase, sonicated and the volume was then made up to 100 
ml with mobile phase. It had been named as stock solution of amlodipine. 
Dilution 1 
5 ml of stock solution of amlodipine was taken in 10 ml volumetric flask and volume was made 
up to 10 ml with mobile phase mixture. This is solution A. 
Dilution 2 
1 ml solution from solution A was taken in 10 ml volumetric flask and volume was made up to 
10 ml with mobile phase mixture. It was named as solution B. 
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Dilution 3 
1 ml solution from solution B was taken in 10 ml volumetric flask and volume was made up to 
10 ml with mobile phase mixture. It was named as solution C. 
Dilution 4 
1 ml solution from solution C was taken in 10 ml volumetric flask and volume was made up to 
10 ml with mobile phase mixture. This is solution D. 
Dilution 5 
1 ml solution from solution D was taken in 10 ml volumetric flask and volume was made up to 
10 ml with mobile phase mixture. This is solution E (Figure 29). 
Data Interpretation: 
The sample concentration o up to 0.095 µg/ml of rosuvastatin and 0.22 µg/ml of amlodipine can 
be readily quantified with the accepted accuracy (Table 15). 
3.2.7. Limit of Detection 
The limit of detection (LOD) is defined as the lowest concentration of an analyte in a sample that 
can be detected. The detection limit is determined by the analysis of sample with known 
concentration of analyte and by establishing the minimum level at which the analyte can be 
reliably detected. The LOD values were determined by formulae LOD = 3.3 σ/m (where, σ is the 
standard deviation of the responses and m is the mean of the slope of the calibration curve).  
 
Table 16: Result of LOD of rosuvastatin calcium and amlodipine besylate 
 Signal height Concentration (µg/ml) 
Rosuvastatin calcium 111 0.06 
Amlodipine besylate 112 0.018 
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Figure 30: Chromatogram of LOD study of rosuvastatin calcium (dilution 4) 
 
 
Figure 31: Chromatogram of LOD study of amlodipine besylate (dilution 5) 
 
 Dilution of Rosuvastatin calcium: 
25 mg of rosuvastatin calcium was accurately weighed in 50 ml volumetric flask. The contents 
were dissolved using mobile phase, sonicated and the volume was made up to 50 ml with mobile 
phase mixture. This is stock solution of rosuvastatin. 
Dilution 1 
12 ml solution from the stock solution of rosuvastatin calcium was taken in a 100 ml volumetric 
flask and volume was made up to 100 ml with mobile phase mixture. This is solution A. 
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Dilution 2 
1 ml solution from solution A was taken in a 10 ml volumetric flask and volume was made up to 
10 ml with mobile phase mixture. This is solution B. 
Dilution 3 
1 ml solution from solution B was taken in a 10 ml volumetric flask and volume was made up to 
10 ml with mobile phase mixture. This is solution C. 
Dilution 4 
1ml solution from solution C was taken in 10 ml volumetric flask and volume was made up to 10 
ml with mobile phase mixture. This is solution D (Figure 30).  
 Dilution of Amlodipine besylate: 
12.5 mg of amlodipine besylate was accurately weighed in 100 ml volumetric flask. The contents were 
dissolved using mobile phase, sonicated and the volume was then made up to 100 ml with mobile phase. 
This is stock solution of amlodipine 
Dilution 1 
5 ml solution was taken out from the stock solution of amlodipine besylate in a 10 ml volumetric flask 
and volume was made up to 10 ml with mobile phase mixture. This is solution A. 
Dilution 2 
3 ml solution from solution A was taken in a 10 ml volumetric flask and volume was made up to 10 ml 
with mobile phase mixture. This is solution B. 
Dilution 3 
1 ml solution from solution B was taken in a 10 ml volumetric flask and volume was made up to 10 ml 
with mobile phase. This is solution C. 
Dilution 4 
1 ml solution from solution C was taken in 10 ml volumetric flask and volume was made up to 10 ml with 
mobile phase mixture. This is solution D. 
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Dilution 5 
1 ml solution from solution D was taken out in a 10 ml volumetric flask and volume was made 
up to 10 ml with mobile phase mixture. This is solution E (Figure 31). 
Data Interpretation: 
The sample concentration up to 0.06 µg/ml of rosuvastatin and 0.018 µg/ml of amlodipine can be 
readily detected with the accepted accuracy (Table 16). 
3.2.8. Robustness 
The robustness of an analytical procedure refers to its ability to remain unaffected by small and 
deliberate variations in method parameters and provides an indication of its reliability for routine 
analysis (Shabir). To determine robustness of the proposed method, % test sample preparations 
were prepared and analyzed by varying analytical parameters while keeping the other parameters 
unchanged such as the composition of mobile phase (±5%), flow rate (±2%), column 
temperature (±5ºC), wavelength (±5) (Figure 32-38). 
 
 
Figure 32: Chromatogram of rosuvastatin and amlodipine at a flow-rate of 1.3 ml/min 
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Figure 33: Chromatogram of rosuvastatin and amlodipine at a flow-rate of 1.7 ml/min 
 
 
 
Figure 34: Chromatogram of rosuvastatin calcium and amlodipine besylate at 20°C 
 
 
Figure 35: Chromatogram of rosuvastatin calcium and amlodipine besylate at 30°C 
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Figure 36: Chromatogram of rosuvastatin calcium and amlodipine besylate at a mobile phase 
ratio ACN:Buffer (42:58) 
 
Figure 37: Chromatogram of rosuvastatin calcium and amlodipine besylate at a mobile phase 
ratio ACN:Buffer (48:52) 
 
                 
(a)                                                                  (b) 
Figure 38: Chromatogram of rosuvastatin and amlodipine at (a) 235 nm & (b) 245 nm 
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Table 17: Result of robustness study of rosuvastatin calcium 
Rosuvastatin 
Flow rate Mobile phase composition` 
Column 
temperature Wavelength 
1.3 1.7 ACN:Buffer 
(48:52) 
ACN:Buffer
(42:58) 20ºC 30ºC 235 nm 245 nm 
ml/min ml/min 
1 72314 139539 158562 155336 157502 157417 156999 157347 
2 72381 139187 157896 155503 157219 157006 157532 157432 
3 72315 139253 158761 155407 157314 157315 157515 157515 
4 72387 139186 158645 155371 157478 157259 157466 157966 
5 72358 139180 158466 155352 157402 157245 157469 157943 
6 72355 139243 158021 155273 157417 157240 157679 157529 
Avg. 72352 139265 158392 155374 157389 157247 157443 157622 
STD. 31.4 138 351.6 77.3 106 135.5 231.1 265.8 
%RSD 0.04 0.10 0.22 0.22 0.07 0.09 0.15 0.17 
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Table 18: Result of robustness study of amlodipine besylate 
Amlodipine 
Flow rate Mobile phase composition` Column temperature Wavelength 
1.3 1.7 ACN:Buffer 
(48:52) 
ACN:Buffer 
(42:58) 
20ºC 30ºC 235 nm 245 nm 
ml/min ml/min 
1 72314 55381 62807 62755 62952 63505 63128 63124 
2 72381 55494 62623 62857 63692 63349 63043 63455 
3 72356 55412 62766 62681 62789 63413 63343 63298 
4 72325 55424 62759 62799 62815 63476 63233 63455 
5 72366 55476 62883 62746 62833 63442 63127 63120 
6 72348 55437 62767 62767 63016 63437 63175 63290.4 
Avg. 72348 55437 62768 62768 63016 63437 63175 63290.4 
STD. 25.1 42 84.7 58.5 342 53.8 103.5 149.0 
%RSD 0.03 0.08 0.13 0.13 0.54 0.08 0.16 0.24 
 
Data interpretation: 
From the above data (Table 17 & 18) it can be concluded that, the results are within the limit. 
Therefore, the method is robust. 
3.3. Data of in­vitro dissolution study 
In the previous section of the study, the validation of the method for estimation of rosuvastatin 
calcium and amlodipine besylate using was done using reverse phase C-18 column (250 x 4.6 
mm, 5 µm) at a wavelength of 240 nm in mobile phase composition containing phosphate buffer 
(pH 2.5) and acetonitrile in the ratio 55:45 % (v/v). This same method was also used for the 
comparative in-vitro dissolution study of formulated combination preparations of rosuvastatin & 
amlodipine with their separate formulation available in the market. For the estimation of the 
particulate release of rosuvastatin and amlodipine, separate dissolution mediums were used 
according to FDA dissolution specifications. For the in vitro dissolution study, three formulated 
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combination preparations of rosuvastatin & amlodipine were compared with the three separate 
market preparations of amlodipine as well as three separate market preparations of rosuvastatin.  
A typical acceptance criterion for dissolution release of drugs from immediate release tablet is 
about 80% of label amount in 45 minutes. The in vitro dissolution profile of the combination 
formulation tablets of rosuvastatin and amlodipine was compared with that of separate 
commercial preparations of amlodipine and rosuvastatin alone by using the proposed HPLC 
method that are shown in Figures 39 & 40. Both marketed and combined formulation 
preparations released on an average 95% rosuvastatin within 45 min whereas on an average 90% 
of amlodipine was released within 45 min from both marketed and formulated preparations 
(tables 19 & 20). The dissolution pattern complies with the BP Guidance standards as well as 
with the in-house specifications (rosuvastatin calcium is an INN drug), indicating suitability of 
the proposed method for the dissolution study of the two drugs. The result of the 
chromatographic study of the marketed and combination preparation of rosuvastatin and 
amlodipine is shown in the following tables (Table 21-24). 
Table 19:  Dissolution profile of rosuvastatin calcium  
Rosuvastatin calcium 
Time interval Dissolution media 
% of drug release 
Formulated combination 
preparation Market preparation 
After 10 min 
0.05 M sodium citrate buffer 
of pH 6.6 
88.03 83.89 
After 20 min 91.65 90.86 
After 30 min 94.06 92.7 
After 45 min 96.99 94.07 
After 60 min 98.5 98 
 
Table 20: Dissolution profile of amlodipine besylate 
Amlodipine  besylate 
Time interval Dissolution media 
% of drug release 
Formulated combination 
preparation Market preparation 
After 10 min 
0.01 N HCl 
58.69 90.08 
After 20 min 71.56 92.16 
After 30 min 83.62 98 
After 45 min 92.56 102 
After 60 min 99.65 105 
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Figure 39: Drug release pattern of rosuvastatin calcium from formulated and market preparation 
 
 
 
Figure 40: Drug release pattern of amlodipine besylate from formulated and market preparation 
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Table 21: Summary of chromatogram of rosuvastatin calcium in formulated Tablets 
 
Rosuvastatin calcium 
 
Retention 
Time 
 
Tailing 
Factor 
 
Theoretical 
Plate 
 
Peak Area 
Formulated Tablet 1 
10 min 6.188 1.032 10791 160162 
20 min 6.186 1.037 10735 158866 
30 min 6.182 1.033 10707 161491 
45 min 6.185 1.033 10841 137665 
60 min 6.184 1.036 10730 168484 
Formulated Tablet 2 
10 min 6.188 1.033 10773 164960 
20 min 6.183 1.036 10756 164678 
30 min 6.182 1.033 10708 166979 
45 min 6.18 1.032 10699 177800 
60 min 6.187 1.033 10848 160015 
Formulated tablet 3 
10 min 6.183 1.036 10677 158950 
20 min 6.189 1.034 10749 162544 
30 min 6.187 1.035 10764 163406 
45 min 6.184 1.033 10717 168975 
60 min 6.198 1.033 10842 160153 
Average 6.186 1.034 10756 162342 
Standard deviation 0.004 0.00162 54.474 8467.9 
Relative standard deviation (%) 0.069 0.1571 0.5065 5.21611 
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Table 22: Summary of chromatogram of rosuvastatin calcium in marketed preparations 
 
Rosuvastatin calcium 
 
Retention 
Time 
 
Tailing 
Factor 
 
Theoretical 
Plate 
 
Peak Area 
Market Rosuvastatin tablet 1 
10 min 6.213 1.03 10875 152098 
20 min 6.163 1.033 10891 160000 
30 min 6.15 1.035 10637 166659 
45 min 6.158 1.034 10530 167584 
60 min 6.177 1.034 10585 169812 
Market Rosuvastatin tablet 2 
10 min 6.209 1.032 10961 160137 
20 min 6.144 1.034 10772 163603 
30 min 6.158 1.034 10633 166850 
45 min 6.169 1.036 10530 162337 
60 min 6.184 1.036 10481 175513 
Market Rosuvastatin tablet 3 
10 min 6.18 1.033 10875 174611 
20 min 6.154 1.036 10772 176374 
30 min 6.163 1.038 10594 183467 
45 min 6.178 1.031 10474 184606 
60 min 6.192 1.033 10429 189395 
Average 6.173 1.034 10669 170203 
Standard Deviation 0.02 0.00209 174.3 10374.7 
Relative standard deviation (%) 0.332 0.2018 1.63 6.095 
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Table 23: Summary of chromatogram of amlodipine besylate in formulated Tablets 
 
Amlodipine besylate 
 
Retention 
time 
 
Tailing 
Factor 
 
Theoretical 
Plate 
 
Peak Area 
Formulated Tablet 1 
10 min 2.594 1.149 6311 100279 
20 min 2.597 1.148 6328 100556 
30 min 2.59 1.162 6502 113767 
45 min 2.594 1.153 6325 115617 
60 min 2.591 1.164 6485 115118 
Formulated Tablet 2 
10 min 2.595 1.148 6317 101213 
20 min 2.596 1.148 6327 103111 
30 min 2.586 1.146 6309 110551 
45 min 2.603 1.153 6617 112022 
60 min 2.589 1.164 6376 115279 
Formulated tablet 3 
10 min 2.6 1.157 6473 105543 
20 min 2.596 1.146 6309 106963 
30 min 2.593 1.153 6557 107788 
45 min 2.591 1.162 6490 101802 
60 min 2.591 1.158 6530 105020 
Average 2.594 1.154 6417 107642 
Standard deviation 0.004 0.0066 108.04 5702 
Relative standard deviation (%) 0.168 0.575 1.68 5.30 
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Table 24: Summary of chromatogram of amlodipine besylate in marketed preparations 
 
Amlodipine 
 
Retention 
time 
 
Tailing 
Factor 
 
Theoretical 
Plate 
 
Peak Area 
Market Amlodipine tablet 1 
10 min 2.587 1.152 6589 133842 
20 min 2.588 1.153 6540 148779 
30 min 2.589 1.158 6444 151720 
45 min 2.584 1.153 6387 153340 
60 min 2.588 1.155 6390 154629 
Market Amlodipine tablet 2 
10 min 2.598 1.154 6440 137873 
20 min 2.587 1.155 6240 137781 
30 min 2.6 1.148 6389 143420 
45 min 2.596 1.147 6385 153770 
60 min 2.594 1.151 6354 156955 
Market Amlodipine tablet 3 
10 min 2.595 1.151 6339 132489 
20 min 2.59 1.158 6362 146266 
30 min 2.587 1.156 6358 152834 
45 min 2.588 1.168 6379 154580 
60 min 2.589 1.153 6362 156578 
Average 2.591 1.154 6397 147657 
Standard Deviation 0.005 0.0050 82.8 8497.4 
Relative Standard Deviation (%) 0.182 0.4293 1.29 5.755 
 
 
Discussion 
63 
 
Chapter 4  
Discussion 
The compatibility study of rosuvastatin calcium and amlodipine besylate with the selected 
excipients came out positive which enabled us to adopt the formula to formulate the combination 
dosage form. In the data analysis of the compatibility study, transmittance of some selected 
functional groups have been observed and studied. The selection of the functional groups is 
basically done based upon the vulnerability of those functional groups in case of instability. For 
rosuvastatin, -OH group of alcoholic and carboxylic acid origin have been observed as they are 
susceptible to initiate any kind of chemical reaction and show possibility to form intermolecular 
and intramolecular –H bond. Another vulnerable group present both in rosuvastatin and 
amlodipine besylate is the sulfone group (S=O) which show susceptibility due to the presence of 
loan pair electrons of oxygen molecule. On the other hand, for amlodipine N-H group of primary 
amine, secondary amine, C=O group of α,β unsaturated ester have been observed and studied 
due to the presence of loan pair electron of nitrogen and oxygen molecule.  
The transmittance of different functional groups of the pure sample of rosuvastatin and 
amlodipine in the IR spectrum were compared with the IR spectrum exhibiting transmittance of 
those same functional groups in presence of all the excipients individually. The expression 
pattern of different functional groups of rosuvastatin and amlodipine seemed uninterrupted in 
presence of excipient. In some spectrum transmittance peak of a particular functional group of 
the pure sample of rosuvastatin and amlodipine get merged with the common functional group 
present in the excipient whereas in some other spectrum the response of some particular 
functional groups of rosuvastatin and amlodipine get subside with the presence of the function 
group of the excipient. There is a presence of similar pattern of transmittance of the selected 
functional groups in the IR spectrum of the particular excipient and pure drug mixture which 
makes them identical to detect and enable to claim them to be compatible with the pure drug. In 
brief, all the excipients show compatibility with pure drug of rosuvastatin and amlodipine which 
ensues the certainty of formulating combination dosage form. 
The proposed method describes a RP‐HPLC procedure employing a Luna 5µ C18 column (250 
mm x 4.60 mm) and a mobile phase composition containing acetonitrile and phosphate buffer in 
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the ratio 45:55 % (v/v). In order to develop the method with good resolutions, the changes in 
proportion of solvents were studied in the initial phase of the study. Acetonitrile, methanol, THF, 
phosphate buffer and water were tested in various ratios and compositions to get an appropriate 
mobile phase composition. The mixtures of acetonitrile, THF and water at various ratios were 
examined at first, which resulted in very good resolutions for the two pure drugs but using them 
for the estimation of the marketed preparations of the drug resulted in some broadening, 
disrupted peak for amlodipine. In addition, the method was not sensitive at all to detect 
rosuvastatin from the marketed formulation. The other reason for discarding the mobile phase 
composition containing acetonitrile, water, THF is the toxicity of THF and their detrimental 
effect after its disposal to the environment. Good resolutions for the two drugs were achieved 
with the mobile phase having a composition of acetonitrile and phosphate buffer in the ratio 
45:55 % (v/v).  
Retention time for both the drugs were also studied with flow rate of mobile phase at 1.3 ml/min, 
1.5ml/min, 1.7 ml/min. Optimum retention time with greater resolution of separate peaks for the 
two drugs were obtained within eight minutes (approx.) with a flow rate of 1.5ml/min. 10 µg/ml 
concentration of two drug solutions were scanned in the UV range of 200 nm to 400 nm on an 
UV‐Visible spectrophotometer. After recording the spectra of the two drugs, 240 nm was 
selected as suitable wavelength for estimation. Hence the method of acetonitrile and phosphate 
buffer in the ratio 45:55 % (v/v) with 1.5ml/min at the detection wavelength of 240 nm was 
selected for the simultaneous estimation of rosuvastatin and amlodipine. 
Accuracy of the selected method was checked by adding known amount of pure drug to each 
known concentration of placebo at 3 different concentration levels. The resulting mixtures were 
run on HPLC by the proposed method. The result of analysis showed excellent recoveries for 
both the drugs ranging from 98 % to 102% for amlodipine & rosuvastatin which suggests the 
accuracy of the method for the simultaneous estimation of rosuvastatin and amlodipine. 
Precision of the method was reflected by percentage of relative standard deviation as 0.111 for 
rosuvastatin and 0.242 for amlodipine which was less than 2%. The limit of detection (LOD) and 
limit of quantification (LOQ) were determined by visual methods as suggested in ICH 
guidelines, which were found to be 0.095 µg/ml and 0.06 μg/ml, respectively for rosuvastatin 
and 0.018µg/ml and 0.22 μg/ml, respectively for amlodipine. The linearity response of the HPLC 
system for rosuvastatin was obtained in the range 8 - 1.2 µg/ml and in the range of 4-6 µg/ml for 
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amlodipine. The robustness of the proposed method was determined by varying different 
parameters and measuring their percentage of relative standard deviation. The percentage 
relative standard deviation was found to be less than 2 % for each of the parameters which are in 
the acceptable limit. 
Moreover, to evaluate the sensitivity of the validated method, in vitro dissolution study was done 
to simultaneously estimate rosuvastatin and amlodipine from their formulated combined 
preparations and separate market formulation. After analyzing the result, it was observed that the 
concentration of the drugs has been increased which indicates that the separate dissolution media 
were suitable enough to conduct the dissolution study of the combined formulation. Furthermore, 
the relative standard deviation of the peak area of the formulated tablets and the separate market 
formulations were found very close and within 6%. Hence, the developed method was itself 
sophisticated enough to estimate simultaneously rosuvastatin calcium and amlodipine besylate 
from any tablet containing the two drugs. 
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Chapter 5  
Concluding Remarks  
The proposed combination formulation of rosuvastatin calcium and amlodipine besylate has 
shown compatibility with the chosen excipients, verified through FT-IR study. The proposed RP- 
HPLC method for the simultaneous estimation of rosuvastatin calcium and amlodipine besylate 
within 8 min (approx) with the use of mobile phase composition containing acetonitrile and 
phosphate buffer in the ratio 45:55 % (v/v) is simple, specific, precise, accurate, robust, and 
economic and validated as per the ICH guidelines and can be applied for the long term stability 
studies as well as for the kinetic studies of the pharmaceutical formulations. The analysis of 
combination tablet formulation containing two drugs gave the satisfactory results and the 
parameters for the two titled drugs met the criteria of ICH guidelines for method validation 
(Table 23). The recovery studies revealed excellent accuracy and high precision of the method. 
Therefore, it can be concluded that the RP-HPLC method developed in this study can be 
conveniently adopted for the routine quality control analysis in the combination formulations. 
The present study can be conveniently applied for the routine analysis of the assay and 
dissolution study of the combination formulation of rosuvastatin calcium and amlodipine 
besylate. As the results of the proposed combination formulation show positive remarks, 
preparations of the combination dosage form of rosuvastatin calcium and amlodipine besylate 
which is not currently available in the market, can be thought of as a formulation and the method 
developed in this study can be reported as an analytical method validation protocol.  
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Table 25: Summary of the validation of assay study of Rosuvastatin calcium and Amlodipine 
besylate 
 
Validation 
Parameter 
 
Acceptance criteria 
 
Results 
Amlodipine 
Besylate 
 
Rosuvastatin 
Calcium 
 
System 
suitability 
The %RSD value of peak area, tailing 
factor, theoretical plate, retention time 
for each peak of rosuvastatin calcium 
and amlodipine besylate should be 
NMT 2% for three replicate injections. 
 
0.308 
 
0.060 
Linearity 
The Correlation Co-efficient (R2) 
should be NLT 0.995 for both 
rosuvastatin calcium and amlodipine 
besylate. 
 
 
0.995 
 
 
0.992 
Accuracy 
Mean % recovery at each level should 
be between 98% & 102% for both 
rosuvastatin calcium and amlodipine 
besylate. 
Mean % recovery at each level 
was found to be between 98% 
& 102% for both rosuvastatin 
calcium and amlodipine 
besylate. 
Precision 
The % RSD value of the peak area of 
rosuvastatin calcium and amlodipine 
besylate obtained from six replicate 
injections should be NMT 2% 
The RSD value of Peak area of 
rosuvastatin calcium and 
amlodipine besylate was found 
within the limit. 
Ruggedness 
The %RSD value of the peak area of 
rosuvastatin calcium and amlodipine 
besylate obtained from six replicate 
injections (done by two different 
analyst) should be NMT 2%. 
The RSD value of Peak area of 
rosuvastatin calcium and 
amlodipine besylate was found 
within the limit. 
 
 
Robustness 
 
The RSD value of the peak area of 
rosuvastatin calcium and amlodipine 
besylate obtained from changing 
different parameter ( like – mobile 
phase ratio, wavelength, temperature 
flow rate) should be within 2 %. 
The RSD value of Peak area of 
rosuvastatin and amlodipine 
was found within the limit. 
 
Concluding Remarks 
68 
 
 
 
 
Appendix 
69 
 
Appendix 
Appendix 1 
Statins 
Statins, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, have shown 
revolution in the treatment of hypercholesterolemia. They are more effective than other lipid-
lowering medications in reducing low-density lipoprotein cholesterol (LDL-C) and total 
cholesterol (total-C) concentrations and are the first choice of drug therapy when this is the 
primary goal of treatment. It competitively blocks HMG-CoA reductase enzyme with respect to 
the binding of the substrate, HMG-CoA since the chemical structure of statin possesses an 
analogue of the target enzyme substrate, HMG-CoA. In addition to that, a complex hydrophobic 
ring structure is covalently linked to the substrate analogue which is involved in binding of the 
statin to the reductase enzyme. 
The liver is the primary site of action at which the statin inhibits the biosynthesis of cholesterol. 
Statins mimic the natural substrate molecule, HMG-CoA and act by competitively blocking the 
HMG-CoA reductase enzyme, which catalyzes the rate-limiting step in de novo cholesterol 
synthesis (Maron et al., 2000). This competition slows the rate of mevalonate production, the 
next molecule in the serial steps to produce cholesterol (Statins: Controlling Cholesterol). Hence, 
in the presence of statins, the precursor HMG-CoA is not efficiently processed forward to 
produce mevalonate, blocking the pathway (Statins: Controlling Cholesterol). Liver cells sense 
the reduced levels of liver cholesterol production with statin use and try to compensate by 
synthesizing more LDL receptors on the cell surface to increase cholesterol uptake from serum 
Statins: Controlling Cholesterol). The LDL and VLDL particles bind and are internalized into 
liver cells, where the cholesterol component is processed into bile salts which clear LDL and 
LDL precursors from the circulation. Plasma levels of low density lipoproteins (LDLs) are 
positively correlated with the incidence of coronary artery disease (CAD). Thus statin therapy 
significantly reduces lipid levels and diminishes the incidence of coronary events in individuals 
with stroke and ischemic heart disease. 
Inhibition of mevalonate systhesis inhibits the synthesis of isoprenoid geranylgeranlpyrp 
phosphate (GGPP) upstream of cholesterol (Thimmaraju et al., 2013). Mevastatin was the first 
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HMG-CoA reductase inhibitor which was isolated from Penicillum citrinum. Other statins such 
as simvastatin, lovastatin and pravastatin are fungal derivatives, while atorvastatin, cerivastatin, 
fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds. As of now, some of the 
commercially marketed statins are atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin 
(Mevacor), simvastatin (Zocor), pitavastatin (Livalo) and rosuvastatin (Creastor) which varies in 
their lipid lowering capacity. Of the statins currently available, rosuvastatin is the most effective 
in lowering LDL-C, with reductions upto 63% reported in the daily dose of 40 mg (Thimmaraju 
et al., 2013). Besides, several combined preparations of statin, with other cholesterol lowering 
drug such as ezetimibe/simvastatin, or with Ca-channel blocker atorvastatin/amlodipine, has 
benefited the patients in achieving recommended lipoprotein level, leading to a decrease in the 
incidence of cardiovascular disease. 
Hepatoselectivity of statins is determined in large part by their hydrophilic properties. 
Hydrophobic statins tend to have higher exposure in non-hepatic tissues, resulting in unwanted 
side effects at other tissues. On the other hand, the hydrophilic statins are more liver specific and 
give them better potency. Atorvastatin, Fluvastatin, Lovastatin and Simvastatin are relatively 
lipophilic compounds, while Pravastatin and Rosuvastatin are more hydrophilic as a result of a 
polar hydroxyl group and methane sulphonamide group, respectively (Srinivasa et al., 2011). Of 
the marketed product, cerivastatin (Baycol) was the most lipophilic and able to diffuse into many 
cell types and exhibiting the most serious adverse effects before it was withdrawn in 2001 
(Statins: Controlling Cholesterol). In addition, comparison of the six statin–enzyme complexes 
revealed subtle differences in their modes of binding. An additional hydrogen bond was 
demonstrated in the atorvastatin– and rosuvastatin–enzyme complexes along with a polar 
interaction unique to Rosuvastatin, such that Rosuvastatin has the most binding interactions with 
HMG-CoA reductase of all the statins (Srinivasa et al., 2011). 
Appendix 2 
Calcium Channel Blocker 
The calcium channel blocking drugs (CCBs) are a heterogeneous group of compounds that are 
classified according to chemical structure: diphenylalkylamines (verapamil), benzothiazepines 
(diltiazem), dihydropyridines (nifedipine, amlodipine, felodipine, nimodipine), and 
diphenylpiperazines (flunarizine) (Drug reference. 2003). They are among the most widely used 
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drugs in cardiovascular medicine with roles not only in hypertension but also in angina and 
tachyarrhythmia. The three classes of CCBs differ not only in their basic chemical structure, but 
also in their relative selectivity toward cardiac versus vascular L-type calcium channels. 
Dihydropyridine, one of the chemical classes of Ca channel blocker, has minimal effect on 
cardiac conduction or heart rate, while they have potent actions as vasodilators because of their 
high selectivity to vascular smooth muscle. Although in vitro the dihydropyridines can depress 
myocardial contractility because of their reflex- mediated sympathetic stimulation on both heart 
rate and contractility. This cardiac stimulation has been associated with the precipitation or 
worsening of angina or even the occurrence of myocardial infarction or sudden death. Reflex-
mediated cardiac stimulation is less likely with the longer-acting and slow-release preparations 
because their slower onset of effect allows baroreflex resetting. 
Amlodipine, considered as a third generation member of dihydropyridine class of calcium 
antagonists with a long duration of action, are primarily used to treat hypertension. It inhibits 
transmembrane influx of extracellular calcium ions across the membranes of myocardial cells 
and vascular smooth muscle cells by selectively blocking voltage-gated L- type calcium 
channels, without changing serum calcium concentrations. When inward calcium flux is 
inhibited, vascular smooth muscle cells relax, resulting in vasodilation of coronary artery and 
arteriole smooth muscle. Vasodilation decreases total peripheral resistance which decreases 
cardiac output. Since blood pressure is determined by cardiac output and peripheral resistance, 
blood pressure drops. Thus lowering of blood pressure will substantially reduce the risk of fatal 
and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also 
indicated for the symptomatic treatment of chronic stable angina because of the long duration of 
action. As an antianginal agent, it acts as a dilator of peripheral arteries and arterioles which 
subsequently reduces the total peripheral resistance and, therefore, reduces the workload of the 
heart (after load). The unloading of the heart thereby decrease ischemia and relieve effort angina 
by reducing myocardial energy oxygen consumption and oxygen requirements.  
CCBs are a class of drugs that should not be prescribed as initial or first line treatment in people 
with high blood pressure who have no other form of heart disease (Kabir et al., 2014). 
Amlodipine, a third generation member of dihydropyridine class of CCBs, has chosen for a 
combination with statins which together provide dose related reduction in systolic blood 
pressure, diastolic blood pressure and LDL-C in patients with co-morbid hypertension and 
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dyslipidemia. Amlodipine is the most reasonable choice among all the other classes of available 
antihypertensive drug such as beta blocker, ACE inhibitor, diuretics and the other calcium 
channel blockers. Compared with other CCBs, amlodipine has greater membrane affinity, owing 
to its positive charge and strong lipophilicity which increases its oral bioavailability. The longer 
duration of elimination half life prolongs the duration of action which decreases the dosing 
frequency and maintains a uniform concentration of the drug. Amlodipine also has antioxidant 
effects, independent of calcium channel modulation, and a vasodilatory effect via the inhibition 
of nitric oxide release, which inhibits platelet aggregation. These pleiotropic effects of 
amlodipine suggest that it is more cardioprotective than other non-CCB-based treatments (Park, 
2014). Amlodipine does not appear to increase neurohormonal activity (epinephrine, renin, 
aldosterone, atrial natriuretic peptide) which also suggests that amlodipine may be safer than 
other CCBs in patients with left ventricular dysfunction or heart failure (Drug reference. 2003). 
The side effects of amlodipine is also less than the other calcium channel blockers which further 
can be minimized by keeping the dose small.  
Appendix 3 
Rosuvastatin calcium 
Rosuvastatin calcium, chemically described as bis [(E)-7 [4-(4-fluorophenyl)-6 isopropyl- 
2[methyl (methyl-sulphonyl) amino] pyrimidin-5-yl] (3R, 5S) -3,5-dihydroxyhept-6-enoic acid] is 
a calcium salt of rosuvastatin. It is a member of statin used in the treatment of hyper-
cholesterolemia and dyslipidemia by selective and competitive inhibition of 3-hydroxy-3-methyl 
glutaryl coenzyme A (HMG-CoA) reductase, the rate limiting enzyme that converts HMGCoA 
to mevalonate a precursor of cholesterol and thereby checks the synthesis of cholesterol. 
Formula: (C22H27FN3O6S)2Ca 
Molecular weight: 1001.14 
Category: Lipid lowering agent 
Pharmacologic class: Synthetic statin 
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Structure: 
 
 
Figure 41: Structure of rosuvastatin calcium 
Physicochemical properties: Rosuvastatin calcium is a hydrophilic white amorphous 
powder with a partition coefficient (octanol/water) of 0.13 at pH of 7.0. 
Solubility: It is sparingly soluble in water and methanol, and slightly soluble in ethanol. 
Mechanism of action: 
Rosuvastatin is a competitive inhibitor of HMG-CoA reductase. HMG-CoA reductase catalyzes 
the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol 
biosynthesis. It acts primarily in the liver. Decreased hepatic cholesterol concentrations stimulate 
increased hepatic uptake of LDL.  Again, it increases the  
number of hepatic LDL (Low Density Lipoprotein)  receptors  on  the  cell‐surface  to  enhance  
uptake  and  catabolism of  LDL (Anuradha et al., 2010). Moreover, it inhibits hepatic synthesis 
of very low density lipoprotein (VLDL), thus depletion in plasma LDL and VLDL level.  
Available formulation: 
Rosuvastatin is available as single pill formulations to impart effective therapeutic effect.  
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Dosing Information: 
Rosuvastatin calcium is supplied in tablets in amounts equivalent to 5 mg, 10 mg, 20 mg, and 40 
mg of Rosuvastatin. In the treatment of hypercholesterolemia, the usual recommended starting 
dosage is 10 mg once a day. An initial dosage of 5 mg once a day should be considered for 
patients requiring less aggressive LDL-C reductions or who have predisposing factors for 
myopathy since higher doses of statins are associated with a greater incidence of myopathy 
(Rosuvastatin, Crestor ). For patients with marked hypercholesterolemia and aggressive lipid 
targets, a starting dosage of 20 mg once a day may be considered (Rosuvastatin, Crestor ). A 
dosage of 40 mg once a day should be reserved for those patients who have not achieved the 
LDL-C goal at a dosage of 20 mg (Rosuvastatin, Crestor). 
Pharmacokinetics: 
a) Absorption:  
 Bioavailability- 20%(first pass metabolism) 
 Peak plasma conc.: 3-5 hours after oral dosing. 
b) Distribution:  
• Volume of Distribution: 134L 
• Plasma protein binding: 88% bound to plasma proteins (mostly albumin). 
Binding is reversible and independent of plasma concentrations. 
c) Metabolism: 
Cytochrome P450 (CYP) 2C9 is primarily responsible for the formation of rosuvastatin's major 
metabolite, N-desmethylrosuvastatin which has approximately 50% of the pharmacological 
activity of its parent compound in vitro. Only ~10% is excreted as metabolite. 
d) Elimination:  
Rosuvastatin and its metabolites are primarily excreted in the feces (90%). 
Appendix 4 
Amlodipine Besylate 
Amlodipine besylate, chemically described as 3-ethyl-5-methyl(±)-2-[(2-aminoethoxy)methyl]-4-
(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5 pyridinedicarboxylate, monobenzenesulphonate, is 
the besylate salt of amlodipine, a long-acting dihydropyridine class of calcium channel blocker, 
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approved for treating hypertension and both vasospastic and chronic, stable angina (Blank, 
2005). 
Molecular weight:  567.05 
Formula: C20H25ClN2O5.C6H6O3S 
Structure: 
 
Figure 42: Structure of amlodipine Besylate 
Category: Anti hypertensive agent 
Pharmacologic class: Calcium L-channel antagonist. 
Physical properties: Amlodipine besylate is a light sensitive white to almost white crystalline 
powder. 
Solubility: It is freely soluble in methanol; sparingly soluble in ethanol and slightly soluble in 2-
prpanol and water. 
pKa: 9 
Mechanism of action: 
As the dihydropyridine class of drugs is more selective for vascular sites than for myocardial 
sites, thus, amlodipine inhibits the transmembrane influx of Ca2+ ion across the membranes by 
selectively blocking voltage-gated L- type calcium channels, without changing serum calcium 
concentrations. Since the influx of calcium ion through calcium channel is important for muscle 
contraction, by blocking calcium transport, it relaxes the muscles lining the arteries and lower 
blood pressure. It also expands coronary arteries which increases the flow of blood to the heart 
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and prevent heart pain (angina) resulting from reduced flow of blood to the heart caused by 
coronary artery spasm (contraction). 
Available Formulation: 
Amlodipine is available both as single pill or combination formulations to impart effective 
antihypertensive effect.  
Dosage and Administration: Dosage should be individualized depending on patient's tolerance 
and responsiveness.  
a) For both hypertension and angina, the recommended initial dose is 5 mg once daily. If 
necessary, dose can be increased after 1 to 2 weeks to a maximum dose of 10 mg once 
daily.  
b) Geriatrics or Patients with Impaired Renal Function: The recommended initial dose in 
patients over 65 years of age or patients with impaired renal function is 5 mg once daily. 
If required, increasing in the dose should be done gradually.  
c) Patients with Impaired Hepatic Function: Dosage requirements have not been established 
in patients with impaired hepatic function. When amlodipine is used in these patients, the 
dosage should be carefully and gradually adjusted depending on patient’s tolerance and 
response. A lower starting dose of 2.5 mg once daily should be considered. 
Pharmacokinetics:   
 Absorption: 
After oral administration of therapeutic doses of amlodipine, absorption occurs gradually from 
the gastrointestinal tract with peak plasma concentration reached between 6 and 9 hours. 
Bioavailability has been estimated 60 to 65%. The bioavailability of amlodipine is not altered by 
the presence of food.  
 Distribution: 
a)  Volume of distribution-21 L per kg.  
b) Protein binding: Very high (> 95 %).  
c) Duration of action: 24 hours. 
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 Biotransformation:  
Amlodipine is metabolized through the cytochrome P450 system, mainly via CYP 3A4 
isoenzyme. It is extensively (about 90%) converted to inactive metabolites (via hepatic 
metabolism) with 10% of the parent compound.  
 Elimination: 
Elimination half life is a mean of 35 hours in healthy volunteers. It may get prolonged to a mean 
of 48 hours in hypertensive patients, 65 hours in the elderly, and 60 hours in patients with 
hepatic function impairment. 
a) Renal—59 to 62% (about 5% as unchanged amlodipine). 
b) Biliary/fecal—20 to 25%.  
c) In dialysis—Amlodipine is not removed by hemodialysis. 
Appendix­5 
FT­IR 
FT-IR or Fourier Transform Infrared spectroscopy is the study of the interaction of 
electromagnetic radiation from the IR region of the EM spectrum (4000-400) cm-1 with a 
molecule through which IR radiation is passed. The nature of interaction depends upon the 
functional groups present into the substance. When IR radiation passed through a sample (solid, 
liquid or gas), certain frequencies of the radiation are absorbed by the atoms of the substance 
leading to molecular vibration. The frequencies of absorbed radiation are unique for each atom 
or group of atom, which provide the characteristics of bonds associated with a substance. The 
resulting spectrum represents the molecular absorption and transmission, which can be divided 
into two approximate regions: 
• Functional group region (4000-1500 cm-1), valuable information are obtained from this 
region to interpret any spectrum. 
• Fingerprint region (<1500 cm-1), usually consists of a very complicated series of 
absorption that are characteristic for a particular compound. Like a fingerprint no two 
unique molecular structures produce the same infrared spectrum. 
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Infrared spectroscopy has been a useful technique for the analysis of materials in the laboratory 
for over seventy years. An infrared spectrum represents a fingerprint of a sample with absorption 
peaks which correspond to the frequencies of vibrations between the bonds of the atoms making 
up the material. As each different material is a unique combination of atoms, no two compounds 
produce the exact same infrared spectrum. Therefore, infrared spectroscopy can result in a 
positive identification (qualitative analysis) of every different kind of material. In addition, the 
size of the peaks in the spectrum is a direct indication of the amount of material present. With 
modern software algorithms, infrared spectroscopy is an excellent tool for quantitative analysis, 
making it useful for several types of analysis: 
a) A qualitative fingerprinting check for the identity of raw materials used in manufacturer 
and for identifying drug. 
b) Used in synthetic chemistry as a preliminary check for presence or absence of functional 
group. 
c) Can be used to characterize sample 
d) Used as a fingerprint test for film, coating and packing plastics 
e) Can be used to detect polymorphs of drug (polymorph are different crystal form of a 
chemical compounds that have different physical properties) 
f) To detect the stability of any substance in presence of another substance 
The original instruments of IR previously were of dispersive type. This type of instrument 
separates the individual frequencies emitted from the infrared source by the use of prism or 
grating and plots a spectrum of intensity versus frequency. The detector measures the amount of 
energy at each frequency which has passed through the sample. A method for measuring all of 
the infrared frequencies simultaneously, rather than individually, was needed. In respect to sort 
out the problem an optical device was developed named “interferometer”. This produces a 
unique type of signal which has all of the infrared frequencies “encoded” into it which can be 
measured very quickly, usually on the order of one second or so. Thus, the time element per 
sample is reduced to a matter of a few seconds rather than several minutes.  
Most interferometers employ a beam splitter which takes the incoming infrared beam and divides 
it into two optical beams. The two beams reflect off of their respective mirrors and are 
recombined when they meet back at the beam splitter. Because the path that one beam travels is a 
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fixed length and the other is constantly changing as its mirror moves, the signal which exits the 
interferometer is the result of these two beams “interfering” with each other (Thermo Nicolet 
Cooperation, 2001). The resulting signal is called an interferogram which has the unique 
property that every data point (a function of the moving mirror position) which makes up the 
signal has information about every infrared frequency which comes from the source (Thermo 
Nicolet Cooperation, 2001). As a frequency spectrum (a plot of the intensity at each individual 
frequency) is required in order to make identification, the measured interferogram signal cannot 
be interpreted directly. A means of “decoding” the individual frequencies is required which can 
be accomplished via a well-known mathematical technique called the Fourier transformation. 
This transformation is performed by the computer which then presents the user with the desired 
spectral information for analysis. In brief, the fourier transform infrared is preferred over the 
dispersive method because of its speed, sensitivity in measurement and non destructive 
technique.  
 
 
Figure 43: Instrumentation of FT-IR 
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Appendix 6 
Reverse Phase – HPLC 
Reversed-phase high-performance liquid chromatography (RP-HPLC) involves the separation of 
molecules on the basis of hydrophobicity. The separation depends on the hydrophobic binding of 
the solute molecule from the mobile phase to the immobilized hydrophobic ligands attached to 
the stationary phase. Decreasing the mobile phase polarity by adding more organic solvent 
reduces the hydrophobic interaction between the solute and the solid support resulting in de-
sorption. The more hydrophobic the molecule the more time it will spend on the solid support 
and the higher the concentration of organic solvent that is required to promote de-sorption.  
In the 1970s, most liquid chromatography was performed using a solid support stationary phase 
containing unmodified silica or alumina resins. This method is now called "normal phase 
chromatography". In normal phase method, the stationary phase is hydrophilic and the 
hydrophilic molecules in the mobile phase will tend to adsorb to the surface on the inside and 
outside of hydrophilic particle. The introduction of a technique using alkyl chains covalently 
bonded to the solid support created a hydrophobic stationary phase, which has a stronger affinity 
for hydrophobic compounds, which is now known as reverse phase HPLC. 
The most popular column used for reverse phase liquid chromatography are octadecyl carbon 
chain (C18)-bonded silica, C8-bonded silica, pure silica, cyano-bonded silica and phenyl-bonded 
silica and for mobile phase mixtures of water or aqueous buffers and organic solvents are usually 
used to elute analytes from a reversed-phase column. The solvents must be miscible with water, 
and the most common organic solvents used are acetonitrile, methanol, and tetrahydrofuran 
(THF). Other solvents can be used such as ethanol or 2-propanol (isopropyl alcohol). 
Appendix­7 
Dissolution 
Dissolution test is required to evaluate the release of drug from a pharmaceutical dosage form as 
a predictor of the in vivo performance of a drug product. A dissolution test is a simple concept, 
where a tablet or capsule is placed into a known volume of media and as it dissolves the resulting 
solution is sampled over time, and assayed (often by HPLC or by spectrophotometry) for the 
level of active pharmaceutical ingredient (API) present. Media volumes are typically kept in the 
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range of 500-1000 ml, with 900 ml the most common volume. Media deaeration is usually 
required which can be accomplished by heating or filtering the medium or placing it under 
vacuum for short period of time. When developing dissolution procedure, one general goal is to 
have “sink” conditions. Sink conditions are defined as the volume of medium that is at least three 
times that required in order to form a saturated solution of drug substance (Vaghela et al., 2011). 
The choice of apparatus is also a matter of consideration during the method development which 
is based on the dosage form performance in the in vitro test system (Table 2) (Vaghela et al., 
2011). 
 
Table 26: USP Apparatus and Agitation Criteria 
USP 
apparatus 
Description Rotation speed Dosage form 
I Basket 
 
50-120 rpm Immediate release 
Delayed release 
Extended release 
II Paddle 25-50 rpm Immediate release  
Delayed release 
Extended release 
III Reciprocating 
cylinder 
 
6-35 rpm Immediate release 
Extended release 
IV Flow through cell 25-50 rpm Extended release, 
 poorly soluble API 
V Paddle over disk N/A Transdermal 
VI Cylinder N/A Transdermal 
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Figure 44: Dissolution Apparatus I and II 
 
Dissolution is evaluated by measuring rate release profile or the amount dissolved over time. So, 
duration is another important criteria need to be considered during the method development of 
dissolution. For immediate release dosage forms, the procedure duration is usually 30 to 60 
minutes and in most cases, single time point specification is adequate (Vaghela et al., 2011). On 
the other hand, for extended release dosage forms, at least three test time points are typically 
chosen to characterize the in vitro drug release profile (Vaghela et al., 2011). At last, for 
analyzing the dissolution test samples, spectrophotometric (UV) determinations and HPLC are 
most commonly used. When a method is developed for particular testing of any specific dosage 
form, that method needs to be validated for the consistency of the results for further conductance 
of the process. 
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